BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Llovet JM, Kelley RK, Villanueva A, Singal AG, Pikarsky E, Roayaie S, Lencioni R, Koike K, Zucman-Rossi J, Finn RS. Hepatocellular carcinoma. Nat Rev Dis Primers 2021;7:6. [PMID: 33479224 DOI: 10.1038/s41572-020-00240-3] [Cited by in Crossref: 96] [Cited by in F6Publishing: 108] [Article Influence: 96.0] [Reference Citation Analysis]
Number Citing Articles
1 Yan G, Chang Z, Wang C, Gong Z, Xin H, Liu Z. LncRNA ILF3-AS1 promotes cell migration, invasion and EMT process in hepatocellular carcinoma via the miR-628-5p/MEIS2 axis to activate the Notch pathway. Dig Liver Dis 2021:S1590-8658(21)00221-8. [PMID: 34053876 DOI: 10.1016/j.dld.2021.04.036] [Reference Citation Analysis]
2 Somé EN, Guingané NA, Ouédraogo H, Tarnagda G, Kouanda S, Sombié R. The hepatocellular carcinoma's risk factors among in-hospital patients at the university-teaching hospital Yalgado Ouédraogo in Ouagadougou, Burkina Faso: A case-control study. Clinical Epidemiology and Global Health 2022;13:100947. [DOI: 10.1016/j.cegh.2021.100947] [Reference Citation Analysis]
3 Wang J, Wang Y, Steffani M, Stöß C, Ankerst D, Friess H, Hüser N, Hartmann D. Novel Risk Classification Based on Pyroptosis-Related Genes Defines Immune Microenvironment and Pharmaceutical Landscape for Hepatocellular Carcinoma. Cancers 2022;14:447. [DOI: 10.3390/cancers14020447] [Reference Citation Analysis]
4 Liu Y, Wang Y, Guo X, He Y, Zhou J, Lv Q, Huang X, Li X. Comparative Effectiveness of Adjuvant Treatment for Resected Hepatocellular Carcinoma: A Systematic Review and Network Meta-Analysis. Front Oncol 2021;11:709278. [PMID: 34540675 DOI: 10.3389/fonc.2021.709278] [Reference Citation Analysis]
5 Moldogazieva NT, Zavadskiy SP, Terentiev AA. Genomic Landscape of Liquid Biopsy for Hepatocellular Carcinoma Personalized Medicine. Cancer Genomics Proteomics 2021;18:369-83. [PMID: 33994362 DOI: 10.21873/cgp.20266] [Reference Citation Analysis]
6 Herold Z, Szasz AM, Dank M. Evidence based tools to improve efficiency of currently administered oncotherapies for tumors of the hepatopancreatobiliary system. World J Gastrointest Oncol 2021;13:1109-20. [PMID: 34616516 DOI: 10.4251/wjgo.v13.i9.1109] [Reference Citation Analysis]
7 Pang S, Shi Y, Xu D, Sun Z, Chen Y, Yang Y, Zhao X, Si-Ma H, Yang N. Screening of Hepatocellular Carcinoma Patients with High Risk of Early Recurrence After Radical Hepatectomy Using a Nomogram Model Based on the γ-Glutamyl Transpeptidase-to-Albumin Ratio. J Gastrointest Surg 2022. [PMID: 35508683 DOI: 10.1007/s11605-022-05326-9] [Reference Citation Analysis]
8 Wang CI, Chu PM, Chen YL, Lin YH, Chen CY. Chemotherapeutic Drug-Regulated Cytokines Might Influence Therapeutic Efficacy in HCC. Int J Mol Sci 2021;22:13627. [PMID: 34948424 DOI: 10.3390/ijms222413627] [Reference Citation Analysis]
9 Fan C, Kam S, Ramadori P. Metabolism-Associated Epigenetic and Immunoepigenetic Reprogramming in Liver Cancer. Cancers (Basel) 2021;13:5250. [PMID: 34680398 DOI: 10.3390/cancers13205250] [Reference Citation Analysis]
10 Yang H, Bae SH, Nam H, Lee HL, Lee SW, Yoo SH, Song MJ, Kwon JH, Nam SW, Choi JY, Yoon SK, Jang JW. A risk prediction model for hepatocellular carcinoma after hepatitis B surface antigen seroclearance. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.032] [Reference Citation Analysis]
11 Ju S, Zhou C, Yang C, Wang C, Liu J, Wang Y, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Apatinib Plus Camrelizumab With/Without Chemoembolization for Hepatocellular Carcinoma: A Real-World Experience of a Single Center. Front Oncol 2022;11:835889. [DOI: 10.3389/fonc.2021.835889] [Reference Citation Analysis]
12 Valenti L, Pedica F, Colombo M. Distinctive features of hepatocellular carcinoma in non-alcoholic fatty liver disease. Dig Liver Dis 2021:S1590-8658(21)00337-6. [PMID: 34294580 DOI: 10.1016/j.dld.2021.06.023] [Reference Citation Analysis]
13 Chen J, Liu J, Xu B, Cao Y, Liang X, Wu F, Shen X, Ma X, Liu J. Ethoxy-erianin phosphate and afatinib synergistically inhibit liver tumor growth and angiogenesis via regulating VEGF and EGFR signaling pathways. Toxicol Appl Pharmacol 2022;:115911. [PMID: 35143806 DOI: 10.1016/j.taap.2022.115911] [Reference Citation Analysis]
14 Chen J, Wang H, Zhou L, Liu Z, Chen H, Tan X. A necroptosis-related gene signature for predicting prognosis, immune landscape, and drug sensitivity in hepatocellular carcinoma. Cancer Med 2022. [PMID: 35560794 DOI: 10.1002/cam4.4812] [Reference Citation Analysis]
15 Liu JKH, Irvine AF, Jones RL, Samson A. Immunotherapies for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34953051 DOI: 10.1002/cam4.4468] [Reference Citation Analysis]
16 Tan DJH, Ng CH, Lin SY, Pan XH, Tay P, Lim WH, Teng M, Syn N, Lim G, Yong JN, Quek J, Xiao J, Dan YY, Siddiqui MS, Sanyal AJ, Muthiah MD, Loomba R, Huang DQ. Clinical characteristics, surveillance, treatment allocation, and outcomes of non-alcoholic fatty liver disease-related hepatocellular carcinoma: a systematic review and meta-analysis. The Lancet Oncology 2022. [DOI: 10.1016/s1470-2045(22)00078-x] [Reference Citation Analysis]
17 Perng P, Lai Y, Lee P, Huang C, Hsu H, Lee J. Safety and Efficacy of Sorafenib and Lenvatinib in Patients Who Underwent Surgery or Whole-Brain Radiotherapy for Brain Metastasis of Hepatocellular Carcinoma. JCM 2022;11:1536. [DOI: 10.3390/jcm11061536] [Reference Citation Analysis]
18 De Muynck K, Vanderborght B, Van Vlierberghe H, Devisscher L. The Gut-Liver Axis in Chronic Liver Disease: A Macrophage Perspective. Cells 2021;10:2959. [PMID: 34831182 DOI: 10.3390/cells10112959] [Reference Citation Analysis]
19 Sun Y, Chen ZY, Gan X, Dai H, Cai D, Liu RH, Zhou JM, Zhang HL, Li ZH, Luo QQ, Jiang S, Wang T, Zhang KH. A novel four-gene signature for predicting the prognosis of hepatocellular carcinoma. Scand J Gastroenterol 2022;:1-11. [PMID: 35512233 DOI: 10.1080/00365521.2022.2069476] [Reference Citation Analysis]
20 Guo Y, Hu J, Zhao Z, Zhong G, Gong J, Cai D. Identification of a Prognostic Model Based on 2-Gene Signature and Analysis of Corresponding Tumor Microenvironment in Alcohol-Related Hepatocellular Carcinoma. Front Oncol 2021;11:719355. [PMID: 34646769 DOI: 10.3389/fonc.2021.719355] [Reference Citation Analysis]
21 Xu D, Wu J, Dong L, Luo W, Li L, Tang D, Liu J. Serpinc1 Acts as a Tumor Suppressor in Hepatocellular Carcinoma Through Inducing Apoptosis and Blocking Macrophage Polarization in an Ubiquitin-Proteasome Manner. Front Oncol 2021;11:738607. [PMID: 34881176 DOI: 10.3389/fonc.2021.738607] [Reference Citation Analysis]
22 Qureshi A, Michel M, Lerner J, Dasanu CA. Evolving therapeutic strategies for advanced hepatocellular carcinoma. Expert Opin Pharmacother 2021;:1-12. [PMID: 34252328 DOI: 10.1080/14656566.2021.1953473] [Reference Citation Analysis]
23 Hu J, Pei W, Jiang Z, Li Z. A combined miR-34a and arsenic trioxide nanodrug delivery system for synergistic inhibition of HCC progression after microwave ablation. Cancer Nano 2021;12. [DOI: 10.1186/s12645-021-00105-8] [Reference Citation Analysis]
24 Vidal-Cevallos P, Chavez-Tapia N. Very-early-stage Hepatocellular Carcinoma, Are We at Long Last on Route for Achieving Better Patient Outcomes? J Clin Transl Hepatol 2021;9:141-2. [PMID: 34007794 DOI: 10.14218/JCTH.2021.00137] [Reference Citation Analysis]
25 Wang RQ, He FZ, Meng Q, Lin WJ, Dong JM, Yang HK, Yang Y, Zhao M, Qiu WT, Xin YJ, Zhou ZL. Tribbles pseudokinase 3 (TRIB3) contributes to the progression of hepatocellular carcinoma by activating the mitogen-activated protein kinase pathway. Ann Transl Med 2021;9:1253. [PMID: 34532390 DOI: 10.21037/atm-21-2820] [Reference Citation Analysis]
26 Davis AM, Scott TA, Morris KV. Harnessing Rift Valley fever virus NSs gene for cancer gene therapy. Cancer Gene Ther 2022. [PMID: 35393569 DOI: 10.1038/s41417-022-00463-4] [Reference Citation Analysis]
27 Zhang D, Zhang Y, Zhang X, Zhai H, Sun X, Li Y. Circ_0046600 promotes hepatocellular carcinoma progression via up-regulating SERBP1 through sequestering miR-1258. Pathol Res Pract 2021;228:153681. [PMID: 34784519 DOI: 10.1016/j.prp.2021.153681] [Reference Citation Analysis]
28 Chen L, Wang Z, Song S, Sun T, Ren Y, Zhang W, Wang M, Liu Y, Zheng C. The Efficacy of Radiotherapy in the Treatment of Hepatocellular Carcinoma with Distant Organ Metastasis. J Oncol 2021;2021:5190611. [PMID: 34840570 DOI: 10.1155/2021/5190611] [Reference Citation Analysis]
29 Liao J, Zeng DN, Li JZ, Hua QM, Huang CX, Xu J, Wu C, Zheng L, Wen WP, Wu Y. Type I IFNs repolarized a CD169+ macrophage population with anti-tumor potentials in hepatocellular carcinoma. Mol Ther 2021:S1525-0016(21)00476-7. [PMID: 34563673 DOI: 10.1016/j.ymthe.2021.09.021] [Reference Citation Analysis]
30 Yin F, Cao N, Xiang X, Feng H, Li F, Li M, Xia Q, Zuo X. DNA Framework-based Topological Aptamer for Differentiating Subtypes of Hepatocellular Carcinoma Cells. Chem Res Chin Univ 2021;37:919-24. [DOI: 10.1007/s40242-021-1159-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Ogasawara S, Koroki K, Kanzaki H, Kobayashi K, Kiyono S, Nakamura M, Kanogawa N, Saito T, Kondo T, Nakagawa R, Nakamoto S, Muroyama R, Chiba T, Kato N. Changes in therapeutic options for hepatocellular carcinoma in Asia. Liver Int 2021. [PMID: 34780081 DOI: 10.1111/liv.15101] [Reference Citation Analysis]
32 Dai HT, Chen B, Tang KY, Zhang GY, Wen CY, Xiang XH, Yang JY, Guo Y, Lin R, Huang YH. Prognostic value of splenic volume in hepatocellular carcinoma patients receiving transarterial chemoembolization. J Gastrointest Oncol 2021;12:1141-51. [PMID: 34295563 DOI: 10.21037/jgo-21-226] [Reference Citation Analysis]
33 Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. JPM 2022;12:738. [DOI: 10.3390/jpm12050738] [Reference Citation Analysis]
34 Liu D, Liu W, Chen X, Yin J, Ma L, Liu M, Zhou X, Xian L, Li P, Tan X, Zhao J, Liao Y, Cao G. circKCNN2 suppresses the recurrence of hepatocellular carcinoma at least partially via regulating miR-520c-3p/methyl-DNA-binding domain protein 2 axis. Clin Transl Med 2022;12:e662. [PMID: 35051313 DOI: 10.1002/ctm2.662] [Reference Citation Analysis]
35 Wang CJ, Guo X, Zhai RQ, Sun C, Xiao G, Chen J, Wei MY, Shao CL, Gu Y. Discovery of penipanoid C-inspired 2-(3,4,5-trimethoxybenzoyl)quinazolin-4(3H)-one derivatives as potential anticancer agents by inhibiting cell proliferation and inducing apoptosis in hepatocellular carcinoma cells. Eur J Med Chem 2021;224:113671. [PMID: 34237623 DOI: 10.1016/j.ejmech.2021.113671] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Jin X, Yin J, Zhu H, Li W, Yu K, Liu M, Zhang X, Lu M, Wan Z, Huang X. SMG9 Serves as an Oncogene to Promote the Tumor Progression via EMT and Wnt/β-Catenin Signaling Pathway in Hepatocellular Carcinoma. Front Pharmacol 2021;12:701454. [PMID: 34456727 DOI: 10.3389/fphar.2021.701454] [Reference Citation Analysis]
37 Li B, Yao J, He F, Liu J, Lin Z, Liu S, Wang W, Wu T, Huang J, Chen K, Fang M, Chen J, Zeng JZ. Synthesis, SAR study, and bioactivity evaluation of a series of Quinoline-Indole-Schiff base derivatives: Compound 10E as a new Nur77 exporter and autophagic death inducer. Bioorg Chem 2021;113:105008. [PMID: 34089944 DOI: 10.1016/j.bioorg.2021.105008] [Reference Citation Analysis]
38 Wei C, Zhu M, Zhang P, Huang X, Wan J, Yao X, Hu Z, Chai X, Peng R, Yang X, Gao C, Gao J, Wang S, Zheng Y, Tang Z, Gao Q, Zhou J, Cai J, Ke A, Fan J. PKCα/ZFP64/CSF1 axis resets the tumor microenvironment and fuels anti-PD1 resistance in hepatocellular carcinoma. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.019] [Reference Citation Analysis]
39 Raissa R, Riawan W, Safitri A, Masruri M, Beltran MAG, Aulanniam A. In vitro and in vivo study: Ethanolic extract leaves of Azadirachta indica Juss. variant of Indonesia and Philippines suppresses tumor growth of hepatocellular carcinoma by inhibiting IL-6/STAT3 signaling. F1000Res 2022;11:477. [DOI: 10.12688/f1000research.109557.1] [Reference Citation Analysis]
40 Li X, Ramadori P, Pfister D, Seehawer M, Zender L, Heikenwalder M. The immunological and metabolic landscape in primary and metastatic liver cancer. Nat Rev Cancer 2021;21:541-57. [PMID: 34326518 DOI: 10.1038/s41568-021-00383-9] [Reference Citation Analysis]
41 Sun R, Zhang L, Yang Z, Zhou K, Tang H, Zhao W, Wang N, Yu X, Huang Y, Xie H, Zheng S, Zhang W. Liver transplantation for Hepatocellular Carcinoma: A prognostic model incorporating pretransplant inflammatory cytokines. Cytokine 2022;153:155847. [PMID: 35303693 DOI: 10.1016/j.cyto.2022.155847] [Reference Citation Analysis]
42 Datfar T, Doulberis M, Papaefthymiou A, Hines IN, Manzini G. Viral Hepatitis and Hepatocellular Carcinoma: State of the Art. Pathogens 2021;10:1366. [PMID: 34832522 DOI: 10.3390/pathogens10111366] [Reference Citation Analysis]
43 Peng D, Fu M, Wang M, Wei Y, Wei X. Targeting TGF-β signal transduction for fibrosis and cancer therapy. Mol Cancer 2022;21. [DOI: 10.1186/s12943-022-01569-x] [Reference Citation Analysis]
44 Vogel A, Saborowski A. Medical therapy of HCC. J Hepatol 2021:S0168-8278(21)00352-4. [PMID: 34538616 DOI: 10.1016/j.jhep.2021.05.017] [Reference Citation Analysis]
45 Nösser M, Feldbrügge L, Pratschke J. Minimally invasive liver surgery: the Charité experience. Turk J Surg 2021;37:199-206. [DOI: 10.47717/turkjsurg.2021.1011] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
46 Zhang L, Zhou L, Zhang H, Zhang Y, Li L, Xie T, Chen Y, Li X, Ling N, Dai J, Sun X, Liu J, Zhao J, Peng T, Ye M. Development of a DNA Aptamer against Multidrug-Resistant Hepatocellular Carcinoma for In Vivo Imaging. ACS Appl Mater Interfaces 2021;13:54656-64. [PMID: 34779207 DOI: 10.1021/acsami.1c12391] [Reference Citation Analysis]
47 Donne R, Sangouard F, Celton-Morizur S, Desdouets C. Hepatocyte Polyploidy: Driver or Gatekeeper of Chronic Liver Diseases. Cancers (Basel) 2021;13:5151. [PMID: 34680300 DOI: 10.3390/cancers13205151] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
48 Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet 2021;398:1359-76. [PMID: 34543610 DOI: 10.1016/S0140-6736(21)01374-X] [Cited by in Crossref: 4] [Article Influence: 4.0] [Reference Citation Analysis]
49 Qi X, Wu F, Kim SH, Kaifi JT, Kimchi ET, Snyder H, Illendula A, Fox T, Kester M, Staveley-O'Carroll KF, Li G. Nanoliposome C6-Ceramide in combination with anti-CTLA4 antibody improves anti-tumor immunity in hepatocellular cancer. FASEB J 2022;36:e22250. [PMID: 35294071 DOI: 10.1096/fj.202101707R] [Reference Citation Analysis]
50 Du H, Gu J, Peng Q, Wang X, Liu L, Shu X, He Q, Tan Y. Berberine Suppresses EMT in Liver and Gastric Carcinoma Cells through Combination with TGFβR Regulating TGF-β/Smad Pathway. Oxid Med Cell Longev 2021;2021:2337818. [PMID: 34712379 DOI: 10.1155/2021/2337818] [Reference Citation Analysis]
51 Yan X, Qu X, Liu B, Zhao Y, Xu L, Yu S, Wang J, Wang L, Su J. Autophagy-Induced HDAC6 Activity During Hypoxia Regulates Mitochondrial Energy Metabolism Through the β-Catenin/COUP-TFII Axis in Hepatocellular Carcinoma Cells. Front Oncol 2021;11:742460. [PMID: 34868939 DOI: 10.3389/fonc.2021.742460] [Reference Citation Analysis]
52 Yao Z, Wen S, Luo J, Hao W, Liang W, Chen Y. Establishment and Validation of an MTORC1 Signaling-Related Gene Signature to Predict Overall Survival in Patients with Hepatocellular Carcinoma. Biomed Res Int 2021;2021:6299472. [PMID: 34853791 DOI: 10.1155/2021/6299472] [Reference Citation Analysis]
53 Ghaderi-Zefrehi H, Rezaei M, Sadeghi F, Heiat M. Genetic polymorphisms in DNA repair genes and hepatocellular carcinoma risk. DNA Repair (Amst) 2021;107:103196. [PMID: 34416543 DOI: 10.1016/j.dnarep.2021.103196] [Reference Citation Analysis]
54 Foerster F, Gairing SJ, Müller L, Galle PR. NAFLD-driven HCC: Safety and efficacy of current and emerging treatment options. J Hepatol 2021:S0168-8278(21)02037-7. [PMID: 34555422 DOI: 10.1016/j.jhep.2021.09.007] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
55 Wu JY, Sun JX, Cheng SQ, Yan ML. ASO Author Reflections: Treatment for Hepatocellular Carcinoma with Bile Duct Tumor Thrombus-Anatomic Resection Should Be Recommended. Ann Surg Oncol 2021. [PMID: 33791902 DOI: 10.1245/s10434-021-09925-9] [Reference Citation Analysis]
56 Li L, Xin Y, Zhang X, Chen Y, Yang Y, Zhou X, Ye F. The effectiveness of Radiofrequency Ablation for Patients with BCLC B1 Stage Hepatocellular Carcinoma downgraded by Transarterial Chemoembolization. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101878] [Reference Citation Analysis]
57 Cui H, Guo D, Zhang X, Zhu Y, Wang Z, Jin Y, Guo W, Zhang S. ENO3 Inhibits Growth and Metastasis of Hepatocellular Carcinoma via Wnt/β-Catenin Signaling Pathway. Front Cell Dev Biol 2021;9:797102. [PMID: 35004693 DOI: 10.3389/fcell.2021.797102] [Reference Citation Analysis]
58 Zhao S, Wu W, Jiang H, Ma L, Pan C, Jin C, Mo J, Wang L, Wang K. Selective Inhibitor of the c-Met Receptor Tyrosine Kinase in Advanced Hepatocellular Carcinoma: No Beneficial Effect With the Use of Tivantinib? Front Immunol 2021;12:731527. [PMID: 34804015 DOI: 10.3389/fimmu.2021.731527] [Reference Citation Analysis]
59 Chen S, Ma W, Shen L, Wu Y, Qi H, Cao F, Huang T, Fan W. Recurrence Beyond the Milan Criteria of HBV-Related Single Hepatocellular Carcinoma of 2-3 cm: Comparison of Resection and Ablation. Front Oncol 2021;11:757149. [PMID: 34733791 DOI: 10.3389/fonc.2021.757149] [Reference Citation Analysis]
60 Mi H, Ho WJ, Yarchoan M, Popel AS. Multi-Scale Spatial Analysis of the Tumor Microenvironment Reveals Features of Cabozantinib and Nivolumab Efficacy in Hepatocellular Carcinoma. Front Immunol 2022;13:892250. [DOI: 10.3389/fimmu.2022.892250] [Reference Citation Analysis]
61 Wang H, Yu S, Cai Q, Ma D, Yang L, Zhao J, Jiang L, Zhang X, Yu Z. The Prognostic Model Based on Tumor Cell Evolution Trajectory Reveals a Different Risk Group of Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:737723. [PMID: 34660596 DOI: 10.3389/fcell.2021.737723] [Reference Citation Analysis]
62 Fang ZS, Zhang Z, Liang ZJ, Long ZR, Xiao Y, Liang ZY, Sun X, Li HM, Huang H. Liquid-Liquid Phase Separation-Related Genes Associated with Tumor Grade and Prognosis in Hepatocellular Carcinoma: A Bioinformatic Study. Int J Gen Med 2021;14:9671-9. [PMID: 34934344 DOI: 10.2147/IJGM.S342602] [Reference Citation Analysis]
63 Li J, Zhao S, Ling Z, Li D, Jia G, Zhao C, Lin X, Dai Y, Jiang H, Wang S, Teekaraman Y. Dual-Energy Computed Tomography Imaging in Early-Stage Hepatocellular Carcinoma: A Preliminary Study. Contrast Media & Molecular Imaging 2022;2022:1-8. [DOI: 10.1155/2022/2146343] [Reference Citation Analysis]
64 Savier E, Simon-Gracia L, Charlotte F, Tuffery P, Teesalu T, Scatton O, Rebollo A. Bi-Functional Peptides as a New Therapeutic Tool for Hepatocellular Carcinoma. Pharmaceutics 2021;13:1631. [PMID: 34683924 DOI: 10.3390/pharmaceutics13101631] [Reference Citation Analysis]
65 Chen H, Zhang C, Zhou Q, Guo Y, Ren Z, Yu Z, Del Turco S. Integrated Bioinformatic Analysis Identifies TIPIN as a Prognostic Biomarker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-15. [DOI: 10.1155/2022/5764592] [Reference Citation Analysis]
66 Wang ZZ, Meng T, Yang MY, Wang W, Zhang Y, Liu Y, Han AQ, Wu J, Wang HX, Qian B, Zhu LX. ALYREF associated with immune infiltration is a prognostic biomarker in hepatocellular carcinoma. Transl Oncol 2022;21:101441. [PMID: 35523010 DOI: 10.1016/j.tranon.2022.101441] [Reference Citation Analysis]
67 Wang W, Cai J, Wen J, Li X, Yu Y, Zhang L, Han Q, Wei Z, Ma Y, Ying F, Xu X, Li W, Yang Q, Sun S, He X, Cai L, Xiao H, Wang Z. Boosting ferroptosis via abplatin(iv) for treatment of platinum-resistant recurrent ovarian cancer. Nano Today 2022;44:101459. [DOI: 10.1016/j.nantod.2022.101459] [Reference Citation Analysis]
68 Lee HK, Lim HM, Park SH, Nam MJ. Knockout of Hepatocyte Growth Factor by CRISPR/Cas9 System Induces Apoptosis in Hepatocellular Carcinoma Cells. J Pers Med 2021;11:983. [PMID: 34683124 DOI: 10.3390/jpm11100983] [Reference Citation Analysis]
69 Lin P, Gao RZ, Wen R, He Y, Yang H. DNA Damage Repair Profiles Alteration Characterize a Hepatocellular Carcinoma Subtype With Unique Molecular and Clinicopathologic Features. Front Immunol 2021;12:715460. [PMID: 34456923 DOI: 10.3389/fimmu.2021.715460] [Reference Citation Analysis]
70 Zhang M, Gao F, Yu X, Zhang Q, Sun Z, He Y, Guo W. LINC00261: a burgeoning long noncoding RNA related to cancer. Cancer Cell Int 2021;21:274. [PMID: 34022894 DOI: 10.1186/s12935-021-01988-8] [Reference Citation Analysis]
71 Chen R, Mabombo PU, Hu H, Qian Y. Complete response after combined chemoembolization and Huaier therapy for pulmonary metastasis of Hepatocellular carcinoma: A case report. Asian J Surg 2022:S1015-9584(22)00276-7. [PMID: 35337720 DOI: 10.1016/j.asjsur.2022.03.035] [Reference Citation Analysis]
72 Luerken L, Haimerl M, Doppler M, Uller W, Beyer LP, Stroszczynski C, Einspieler I. Update on Percutaneous Local Ablative Procedures for the Treatment of Hepatocellular Carcinoma. Rofo 2022. [PMID: 35545102 DOI: 10.1055/a-1768-0954] [Reference Citation Analysis]
73 Chrysavgis L, Giannakodimos I, Diamantopoulou P, Cholongitas E. Non-alcoholic fatty liver disease and hepatocellular carcinoma: Clinical challenges of an intriguing link. World J Gastroenterol 2022;28:310-31. [PMID: 35110952 DOI: 10.3748/wjg.v28.i3.310] [Reference Citation Analysis]
74 Li HZ, Tan J, Tang T, An TZ, Li JX, Xiao YD. Chemoembolization Plus Microwave Ablation vs Chemoembolization Alone in Unresectable Hepatocellular Carcinoma Beyond the Milan Criteria: A Propensity Scoring Matching Study. J Hepatocell Carcinoma 2021;8:1311-22. [PMID: 34754838 DOI: 10.2147/JHC.S338456] [Reference Citation Analysis]
75 Bozward AG, Warricker F, Oo YH, Khakoo SI. Natural Killer Cells and Regulatory T Cells Cross Talk in Hepatocellular Carcinoma: Exploring Therapeutic Options for the Next Decade. Front Immunol 2021;12:643310. [PMID: 33995362 DOI: 10.3389/fimmu.2021.643310] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
76 Ebeling Barbier C, Heindryckx F, Lennernäs H. Limitations and Possibilities of Transarterial Chemotherapeutic Treatment of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:13051. [PMID: 34884853 DOI: 10.3390/ijms222313051] [Reference Citation Analysis]
77 Zhu S, Chen Y, Ye H, Wang B, Lan X, Wang H, Ding S, He X. Circ-LARP1B knockdown restrains the tumorigenicity and enhances radiosensitivity by regulating miR-578/IGF1R axis in hepatocellular carcinoma. Annals of Hepatology 2022. [DOI: 10.1016/j.aohep.2022.100678] [Reference Citation Analysis]
78 Romualdo GR, Leroy K, Costa CJS, Prata GB, Vanderborght B, da Silva TC, Barbisan LF, Andraus W, Devisscher L, Câmara NOS, Vinken M, Cogliati B. In Vivo and In Vitro Models of Hepatocellular Carcinoma: Current Strategies for Translational Modeling. Cancers (Basel) 2021;13:5583. [PMID: 34771745 DOI: 10.3390/cancers13215583] [Reference Citation Analysis]
79 Rinaldi R, Miglionico R, Nigro I, D'Orsi R, Chiummiento L, Funicello M, Lupattelli P, Laurenzana I, Sgambato A, Monné M, Bisaccia F, Armentano MF. Two Novel Precursors of the HIV-1 Protease Inhibitor Darunavir Target the UPR/Proteasome System in Human Hepatocellular Carcinoma Cell Line HepG2. Cells 2021;10:3052. [PMID: 34831275 DOI: 10.3390/cells10113052] [Reference Citation Analysis]
80 Butterworth J, Gregoire D, Peter M, Roca Suarez AA, Desandré G, Simonin Y, Virzì A, Zine El Aabidine A, Guivarch M, Andrau JC, Bertrand E, Assenat E, Lupberger J, Hibner U. GOLT1B Activation in Hepatitis C Virus-Infected Hepatocytes Links ER Trafficking and Viral Replication. Pathogens 2021;11:46. [PMID: 35055994 DOI: 10.3390/pathogens11010046] [Reference Citation Analysis]
81 Chen Z, Lin X, Wan Z, Xiao M, Ding C, Wan P, Li Q, Zheng S. High Expression of EZH2 Mediated by ncRNAs Correlates with Poor Prognosis and Tumor Immune Infiltration of Hepatocellular Carcinoma. Genes 2022;13:876. [DOI: 10.3390/genes13050876] [Reference Citation Analysis]
82 Álvarez-Mercado AI, Caballeria-Casals A, Rojano-Alfonso C, Chávez-Reyes J, Micó-Carnero M, Sanchez-Gonzalez A, Casillas-Ramírez A, Gracia-Sancho J, Peralta C. Insights into Growth Factors in Liver Carcinogenesis and Regeneration: An Ongoing Debate on Minimizing Cancer Recurrence after Liver Resection. Biomedicines 2021;9:1158. [PMID: 34572344 DOI: 10.3390/biomedicines9091158] [Reference Citation Analysis]
83 Chen X, Lu Y, Shi X, Han G, Zhang L, Ni C, Zhao J, Gao Y, Wang X. Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma. Front Oncol 2022;12:864106. [DOI: 10.3389/fonc.2022.864106] [Reference Citation Analysis]
84 Marin JJG, Romero MR, Herraez E, Asensio M, Ortiz-Rivero S, Sanchez-Martin A, Fabris L, Briz O. Mechanisms of Pharmacoresistance in Hepatocellular Carcinoma: New Drugs but Old Problems. Semin Liver Dis 2021. [PMID: 34544160 DOI: 10.1055/s-0041-1735631] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
85 Feng S, Yu X, Liang W, Li X, Zhong W, Hu W, Zhang H, Feng Z, Song M, Zhang J, Zhang X. Development of a Deep Learning Model to Assist With Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:762733. [DOI: 10.3389/fonc.2021.762733] [Reference Citation Analysis]
86 Yin X, Zhang J, Zhao W, Liu Z, Wang J. Combined Levo-tetrahydropalmatine and diphenyleneiodonium chloride enhances antitumor activity in hepatocellular carcinoma. Pharmacological Research 2022;179:106219. [DOI: 10.1016/j.phrs.2022.106219] [Reference Citation Analysis]
87 Wu Z, Tang H, Wang L, Jin X, Lei Z, Yang P, Zhou J. Postoperative survival analysis of hepatocellular carcinoma patients with liver cirrhosis based on propensity score matching. BMC Surg 2022;22:103. [PMID: 35313836 DOI: 10.1186/s12893-022-01556-5] [Reference Citation Analysis]
88 Parisse S, Ferri F, Persichetti M, Mischitelli M, Abbatecola A, Di Martino M, Lai Q, Carnevale S, Lucatelli P, Bezzi M, Rossi M, De Santis A, Spagnoli A, Ginanni Corradini S. Low serum magnesium concentration is associated with the presence of viable hepatocellular carcinoma tissue in cirrhotic patients. Sci Rep 2021;11:15184. [PMID: 34312420 DOI: 10.1038/s41598-021-94509-6] [Reference Citation Analysis]
89 Stickel F, Hampe J. Rs708113 in WNT3A-WNT9A and hepatocellular carcinoma risk. Lancet Oncol 2022;23:14-6. [PMID: 34902337 DOI: 10.1016/S1470-2045(21)00663-X] [Reference Citation Analysis]
90 Wen K, Yan Y, Shi J, Hu L, Wang W, Liao H, Li H, Zhu Y, Mao K, Xiao Z. Construction and Validation of a Combined Ferroptosis and Hypoxia Prognostic Signature for Hepatocellular Carcinoma. Front Mol Biosci 2021;8:809672. [PMID: 34977159 DOI: 10.3389/fmolb.2021.809672] [Reference Citation Analysis]
91 Huschka H, Mihm S. Hepatic IFNL4 Gene Activation in Hepatocellular Carcinoma Patients with Regard to Etiology. Int J Mol Sci 2021;22:7803. [PMID: 34360569 DOI: 10.3390/ijms22157803] [Reference Citation Analysis]
92 Su K, Yuan Q, Hou H, Ke C, Huang C, Li S, Sun J, Yuan X, Lin Y, Chen Y, Xin H, Liang X, Du Z, Yuan Z. EV-T synergizes with AZD5582 to overcome TRAIL resistance through concomitant suppression of cFLIP, MCL-1, and IAPs in hepatocarcinoma. J Mol Med (Berl) 2022. [PMID: 35247069 DOI: 10.1007/s00109-022-02180-9] [Reference Citation Analysis]
93 Hu J, Mao F, Li L, Wang X, Cai D, He L, Wu Q, Wang C, Zhang N, Ma Y, Wu X, Qu K, Wang X. Analysis of the Heterogeneity of the Tumor Microenvironment and the Prognosis and Immunotherapy Response of Different Immune Subtypes in Hepatocellular Carcinoma. J Oncol 2022;2022:1087399. [PMID: 35401750 DOI: 10.1155/2022/1087399] [Reference Citation Analysis]
94 Repáraz D, Ruiz M, Llopiz D, Silva L, Vercher E, Aparicio B, Egea J, Tamayo-Uria I, Hervás-Stubbs S, García-Balduz J, Castro C, Iñarrairaegui M, Tagliamonte M, Mauriello A, Cavalluzzo B, Buonaguro L, Rohrer C, Heim K, Tauber C, Hofmann M, Thimme R, Sangro B, Sarobe P. Neoantigens as potential vaccines in hepatocellular carcinoma. J Immunother Cancer 2022;10:e003978. [PMID: 35193931 DOI: 10.1136/jitc-2021-003978] [Reference Citation Analysis]
95 Mattos ÂZ, Debes JD, Dhanasekaran R, Benhammou JN, Arrese M, Patrício ALV, Zilio AC, Mattos AA. Hepatocellular carcinoma in nonalcoholic fatty liver disease: A growing challenge. World J Hepatol 2021; 13(9): 1107-1121 [PMID: 34630878 DOI: 10.4254/wjh.v13.i9.1107] [Reference Citation Analysis]
96 Zhang C, Shi Y, Wu L, Wang C, Liao N, Wang F, Zhao B, Wang Y, Liu X. Far-Red Light Triggered Production of Bispecific T Cell Engagers (BiTEs) from Engineered Cells for Antitumor Application. ACS Synth Biol 2022. [PMID: 35113526 DOI: 10.1021/acssynbio.1c00523] [Reference Citation Analysis]
97 Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. [PMID: 33762733 DOI: 10.1038/s41586-021-03362-0] [Cited by in Crossref: 41] [Cited by in F6Publishing: 45] [Article Influence: 41.0] [Reference Citation Analysis]
98 Jin Z, Sun D, Song M, Zhu W, Liu H, Wang J, Shi G, Wang F. Comprehensive Analysis of HOX Family Members as Novel Diagnostic and Prognostic Markers for Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-17. [DOI: 10.1155/2022/5758601] [Reference Citation Analysis]
99 Huang C, Zhang C, Sheng J, Wang D, Zhao Y, Qian L, Xie L, Meng Z. Identification and Validation of a Tumor Microenvironment-Related Gene Signature in Hepatocellular Carcinoma Prognosis. Front Genet 2021;12:717319. [PMID: 34899826 DOI: 10.3389/fgene.2021.717319] [Reference Citation Analysis]
100 Feng G, Cheng Y, Chen K, Shi Z, Solimando AG. Correlation between Immunohistochemical Markers in Hepatocellular Carcinoma Cells and In Vitro High-Throughput Drug Sensitivity Screening. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-12. [DOI: 10.1155/2022/5969716] [Reference Citation Analysis]
101 Chen PY, Tsai TJ, Yang HY, Chou CK, Chang LJ, Chen TH, Hsu MT, Fang CC, Su CC, Lin YL, Feng YM, Chen CY. The Incidence of Bacteremia and Risk Factors of Post-Radiofrequency Ablation Fever for Patients with Hepato-Cellular Carcinoma. Cancers (Basel) 2021;13:5303. [PMID: 34771466 DOI: 10.3390/cancers13215303] [Reference Citation Analysis]
102 Tan AT, Bertoletti A. HBV-HCC treatment with mRNA electroporated HBV-TCR T cells. Immunotherapy Advances 2022;2:ltab026. [DOI: 10.1093/immadv/ltab026] [Reference Citation Analysis]
103 Chen H, Li Z, Wu F, Ji W, Lu L, Wu Z, Huang Y, Wang W, Li S. BCL10 correlates with bad prognosis and immune infiltration of tumor microenvironment in hepatocellular carcinoma. IUBMB Life. [DOI: 10.1002/iub.2581] [Reference Citation Analysis]
104 Shen J, Shen H, Ke L, Chen J, Dang X, Liu B, Hua Y. Knowledge Mapping of Immunotherapy for Hepatocellular Carcinoma: A Bibliometric Study. Front Immunol 2022;13:815575. [DOI: 10.3389/fimmu.2022.815575] [Reference Citation Analysis]
105 Lisi L, Lacal PM, Martire M, Navarra P, Graziani G. Clinical experience with CTLA-4 blockade for cancer immunotherapy: From the monospecific monoclonal antibody ipilimumab to probodies and bispecific molecules targeting the tumor microenvironment. Pharmacol Res 2021;175:105997. [PMID: 34826600 DOI: 10.1016/j.phrs.2021.105997] [Reference Citation Analysis]
106 Zhang J, Chen Y, Zhou C, Liu J, Liu S, Shi H, Zu Q, Solimando AG. Efficacy and Safety of the Combination of Transarterial Chemoembolization with Camrelizumab plus Apatinib for Advanced Hepatocellular Carcinoma: A Retrospective Study of 38 Patients from a Single Center. Canadian Journal of Gastroenterology and Hepatology 2022;2022:1-6. [DOI: 10.1155/2022/7982118] [Reference Citation Analysis]
107 Iwamoto H, Shimose S, Noda Y, Shirono T, Niizeki T, Nakano M, Okamura S, Kamachi N, Suzuki H, Sakai M, Kajiwara A, Itano S, Tanaka M, Yamaguchi T, Kuromatsu R, Koga H, Torimura T, On Behalf Of The Kurume Liver Cancer Study Group Of Japan. Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice. Cancers (Basel) 2021;13:2786. [PMID: 34205099 DOI: 10.3390/cancers13112786] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
108 Singal AG, Nagar SP, Hitchens A, Davis KL, Iyer S. Real-World Effectiveness of Lenvatinib in Hepatocellular Carcinoma Patients with Nonalcoholic Steatohepatitis. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01258-1. [PMID: 34813942 DOI: 10.1016/j.cgh.2021.11.020] [Reference Citation Analysis]
109 Liu T, Yuan Z, Wang H, Wang J, Xue L. Peroxisome-Related Genes in Hepatocellular Carcinoma Correlated with Tumor Metabolism and Overall Survival. Clin Res Hepatol Gastroenterol 2021;:101835. [PMID: 34798303 DOI: 10.1016/j.clinre.2021.101835] [Reference Citation Analysis]
110 Baretti M, Kim AK, Anders RA. Expanding the immunotherapy roadmap for hepatocellular carcinoma. Cancer Cell 2022;40:252-4. [PMID: 35290785 DOI: 10.1016/j.ccell.2022.02.017] [Reference Citation Analysis]
111 Dakua SP, Nayak A. A review on treatments of hepatocellular carcinoma—role of radio wave ablation and possible improvements. Egypt Liver Journal 2022;12. [DOI: 10.1186/s43066-022-00191-2] [Reference Citation Analysis]
112 Shao YY, Chen PS, Lin LI, Lee BS, Ling A, Cheng AL, Hsu C, Ou DL. Low miR-10b-3p associated with sorafenib resistance in hepatocellular carcinoma. Br J Cancer 2022. [PMID: 35236936 DOI: 10.1038/s41416-022-01759-w] [Reference Citation Analysis]
113 Araújo JDL, da Cruz LB, Diniz JOB, Ferreira JL, Silva AC, de Paiva AC, Gattass M. Liver segmentation from computed tomography images using cascade deep learning. Comput Biol Med 2021;140:105095. [PMID: 34902610 DOI: 10.1016/j.compbiomed.2021.105095] [Reference Citation Analysis]
114 Liu L, Xie S, Teng Y, Deng Z, Chen K, Liu H, Huo R, Liang X, Guo P, Yang D, Ma L, Xiang B, Li L, Zhong J. Outcomes of Liver Resection for Metabolic Dysfunction-Associated Fatty Liver Disease or Chronic Hepatitis B-Related HCC. Front Oncol 2022;11:783339. [DOI: 10.3389/fonc.2021.783339] [Reference Citation Analysis]
115 Sweed D, Sultan MM, Mosbeh A, Fayed YA, Abdelsameea E, Ehsan NA, Abdel-Rahman MH, Waked I. Lymphoepithelioma-like Hepatocellular Carcinoma: a Case Report and Review of Literature. J Gastrointest Cancer 2021. [PMID: 34813031 DOI: 10.1007/s12029-021-00757-0] [Reference Citation Analysis]
116 Guo WY, Li RR, Fu YX, Liu SY, Liu GZ, Yang WC, Yang GF. Pyroglutamate Aminopeptidase I Promotes Hepatocellular Carcinoma via IL-6/STAT3 Activation as Revealed by a Specific Biosensor. Anal Chem 2021;93:13311-8. [PMID: 34569224 DOI: 10.1021/acs.analchem.1c03011] [Reference Citation Analysis]
117 Espejo-Cruz ML, González-Rubio S, Zamora-Olaya J, Amado-Torres V, Alejandre R, Sánchez-Frías M, Ciria R, De la Mata M, Rodríguez-Perálvarez M, Ferrín G. Circulating Tumor Cells in Hepatocellular Carcinoma: A Comprehensive Review and Critical Appraisal. Int J Mol Sci 2021;22:13073. [PMID: 34884878 DOI: 10.3390/ijms222313073] [Reference Citation Analysis]
118 Lucatelli P, Burrel M, Guiu B, de Rubeis G, van Delden O, Helmberger T. CIRSE Standards of Practice on Hepatic Transarterial Chemoembolisation. Cardiovasc Intervent Radiol 2021;44:1851-67. [PMID: 34694454 DOI: 10.1007/s00270-021-02968-1] [Reference Citation Analysis]
119 Ortega JF, Heidor R, Auriemo AP, Affonso JM, D'Amico T, Herz C, de Conti A, Ract J, Gioieli LA, Purgatto E, Lamy E, Pogribny I, Moreno FS. Butyrate-containing structured lipids act on HDAC4, HDAC6, DNA damage and telomerase activity during promotion of experimental hepatocarcinogenesis. Carcinogenesis 2021:bgab039. [PMID: 33999989 DOI: 10.1093/carcin/bgab039] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
120 Yao F, Deng Y, Zhao Y, Mei Y, Zhang Y, Liu X, Martinez C, Su X, Rosato RR, Teng H, Hang Q, Yap S, Chen D, Wang Y, Chen MM, Zhang M, Liang H, Xie D, Chen X, Zhu H, Chang JC, You MJ, Sun Y, Gan B, Ma L. A targetable LIFR-NF-κB-LCN2 axis controls liver tumorigenesis and vulnerability to ferroptosis. Nat Commun 2021;12:7333. [PMID: 34921145 DOI: 10.1038/s41467-021-27452-9] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
121 Hou Z, Liu J, Jin Z, Qiu G, Xie Q, Mi S, Huang J. Use of chemotherapy to treat hepatocellular carcinoma. Biosci Trends 2022. [PMID: 35173139 DOI: 10.5582/bst.2022.01044] [Reference Citation Analysis]
122 Kong J, Yu G, Si W, Li G, Chai J, Liu Y, Liu J. Second Primary Malignancies in Patients With Hepatocellular Carcinoma: A Population-Based Analysis. Front Oncol 2021;11:713637. [PMID: 34497765 DOI: 10.3389/fonc.2021.713637] [Reference Citation Analysis]
123 Wang Y, Kui L, Wang G. Combination therapy for HCC: from CRISPR screening to the design of clinical therapies. Signal Transduct Target Ther 2021;6:359. [PMID: 34608130 DOI: 10.1038/s41392-021-00775-1] [Reference Citation Analysis]
124 Kunadirek P, Ariyachet C, Sriphoosanaphan S, Pinjaroen N, Sirichindakul P, Nookaew I, Chuaypen N, Tangkijvanich P. Identification of BHLHE40 expression in peripheral blood mononuclear cells as a novel biomarker for diagnosis and prognosis of hepatocellular carcinoma. Sci Rep 2021;11:11201. [PMID: 34045534 DOI: 10.1038/s41598-021-90515-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
125 Lewin M, Laurent-Bellue A, Desterke C, Radu A, Feghali JA, Farah J, Agostini H, Nault JC, Vibert E, Guettier C. Evaluation of perfusion CT and dual-energy CT for predicting microvascular invasion of hepatocellular carcinoma. Abdom Radiol (NY) 2022. [PMID: 35419748 DOI: 10.1007/s00261-022-03511-7] [Reference Citation Analysis]
126 Zhou H, Yang W, Zhou W. The CRAFITY score: A new guidepost for prognosis prediction in patients with hepatocellular carcinoma undergoing immunotherapy. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2021.12.033] [Reference Citation Analysis]
127 Wang C, Shang C, Gai X, Song T, Han S, Liu Q, Zheng X. Sulfatase 2-Induced Cancer-Associated Fibroblasts Promote Hepatocellular Carcinoma Progression via Inhibition of Apoptosis and Induction of Epithelial-to-Mesenchymal Transition. Front Cell Dev Biol 2021;9:631931. [PMID: 33889573 DOI: 10.3389/fcell.2021.631931] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
128 Dai T, Li J, Lu X, Ye L, Yu H, Zhang L, Deng M, Zhu S, Liu W, Wang G, Yang Y. Prognostic Role and Potential Mechanisms of the Ferroptosis-Related Metabolic Gene Signature in Hepatocellular Carcinoma. Pharmgenomics Pers Med 2021;14:927-45. [PMID: 34377010 DOI: 10.2147/PGPM.S319524] [Reference Citation Analysis]
129 Yang Y, Wu J, Liu F, He J, Wu F, Chen J, Jiang Z. IGF2BP1 Promotes the Liver Cancer Stem Cell Phenotype by Regulating MGAT5 mRNA Stability by m6A RNA Methylation. Stem Cells Dev 2021;30:1115-25. [PMID: 34514861 DOI: 10.1089/scd.2021.0153] [Reference Citation Analysis]
130 Tan CT, Soh NJH, Chang HC, Yu VC. p62/SQSTM1 in liver diseases: the usual suspect with multifarious identities. FEBS J 2021. [PMID: 34882306 DOI: 10.1111/febs.16317] [Reference Citation Analysis]
131 Contreras L, Rodríguez-gil A, Muntané J, de la Cruz J. Broad Transcriptomic Impact of Sorafenib and Its Relation to the Antitumoral Properties in Liver Cancer Cells. Cancers 2022;14:1204. [DOI: 10.3390/cancers14051204] [Reference Citation Analysis]
132 Llovet JM, Castet F, Heikenwalder M, Maini MK, Mazzaferro V, Pinato DJ, Pikarsky E, Zhu AX, Finn RS. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol 2021. [PMID: 34764464 DOI: 10.1038/s41571-021-00573-2] [Reference Citation Analysis]
133 Bian M, Fan R, Yang Z, Chen Y, Xu Z, Lu Y, Liu W. Pt(II)-NHC Complex Induces ROS-ERS-Related DAMP Balance to Harness Immunogenic Cell Death in Hepatocellular Carcinoma. J Med Chem 2022. [PMID: 35025488 DOI: 10.1021/acs.jmedchem.1c01248] [Reference Citation Analysis]
134 Trépo E, Caruso S, Yang J, Imbeaud S, Couchy G, Bayard Q, Letouzé E, Ganne-Carrié N, Moreno C, Oussalah A, Féray C, Blanc JF, Clément B, Hillon P, Boursier J, Paradis V, Calderaro J, Gnemmi V, Nault JC, Guéant JL, Devière J, Archambeaud I, Vitellius C, Turlin B, Bronowicki JP, Gustot T, Sutton A, Ziol M, Nahon P, Zucman-Rossi J; GENTHEP Consortium. Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study. Lancet Oncol 2021:S1470-2045(21)00603-3. [PMID: 34902334 DOI: 10.1016/S1470-2045(21)00603-3] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
135 Liu J, Yang D, Wang X, Asare PT, Zhang Q, Na L, Shao L. Gut Microbiota Targeted Approach in the Management of Chronic Liver Diseases. Front Cell Infect Microbiol 2022;12:774335. [DOI: 10.3389/fcimb.2022.774335] [Reference Citation Analysis]
136 Qu L, Ma X, Fan D. Ginsenoside Rk3 Suppresses Hepatocellular Carcinoma Development through Targeting the Gut-Liver Axis. J Agric Food Chem 2021;69:10121-37. [PMID: 34415764 DOI: 10.1021/acs.jafc.1c03279] [Reference Citation Analysis]
137 Qi F, Qin W, Zhang Y, Luo Y, Niu B, An Q, Yang B, Shi K, Yu Z, Chen J, Cao X, Xia J. Sulfarotene, a synthetic retinoid, overcomes stemness and sorafenib resistance of hepatocellular carcinoma via suppressing SOS2-RAS pathway. J Exp Clin Cancer Res 2021;40:280. [PMID: 34479623 DOI: 10.1186/s13046-021-02085-4] [Reference Citation Analysis]
138 Zhang S, Zhao H, Chen Y, Zhang Y, Zhong WL. GNL3 Regulates SIRT1 Transcription and Promotes Hepatocellular Carcinoma Stem Cell-Like Features and Metastasis. Journal of Oncology 2022;2022:1-11. [DOI: 10.1155/2022/1555670] [Reference Citation Analysis]
139 Elgenidy A, Afifi AM, Awad AK, Jalal PK. Utility of serum angiopoietin-2 as diagnostic marker of hepatocellular carcinoma: a systematic review and diagnostic test accuracy meta-analysis. Clinics and Research in Hepatology and Gastroenterology 2022. [DOI: 10.1016/j.clinre.2022.101909] [Reference Citation Analysis]
140 Nimitrungtawee N, Inmutto N, Chattipakorn SC, Chattipakorn N. Extracellular vesicles as a new hope for diagnosis and therapeutic intervention for hepatocellular carcinoma. Cancer Med 2021. [PMID: 34708589 DOI: 10.1002/cam4.4370] [Reference Citation Analysis]
141 Liu S, Zhang Y, Qiu L, Zhang S, Meng Y, Huang C, Chen Z, Zhang B, Han J. Uncovering N4-Acetylcytidine-Related mRNA Modification Pattern and Landscape of Stemness and Immunity in Hepatocellular Carcinoma. Front Cell Dev Biol 2022;10:861000. [DOI: 10.3389/fcell.2022.861000] [Reference Citation Analysis]
142 Elbaz T, Waked I, El-Akel W, Shaker MK, Abdelaziz AO, Yousif M, El-Bendary M, Zaky S, AbdAllah M, Hassany M, Esmat G, Doss W. Impact of successful HCV treatment using direct acting antivirals on recurrence of well ablated hepatocellular carcinoma. Expert Rev Anti Infect Ther 2021;:1-8. [PMID: 34253123 DOI: 10.1080/14787210.2021.1951230] [Reference Citation Analysis]
143 Gao Q, Anwar IJ, Abraham N, Barbas AS. Liver Transplantation for Hepatocellular Carcinoma after Downstaging or Bridging Therapy with Immune Checkpoint Inhibitors. Cancers (Basel) 2021;13:6307. [PMID: 34944927 DOI: 10.3390/cancers13246307] [Reference Citation Analysis]
144 Yao J, Liang X, Liu Y, Li S, Zheng M. Trends in Incidence and Prognostic Factors of Two Subtypes of Primary Liver Cancers: A Surveillance, Epidemiology, and End Results-Based Population Study. Cancer Control 2022;29:10732748211051548. [PMID: 35147456 DOI: 10.1177/10732748211051548] [Reference Citation Analysis]
145 Liu Y, Duan C, Dai R, Zeng Y. Ferroptosis-mediated Crosstalk in the Tumor Microenvironment Implicated in Cancer Progression and Therapy. Front Cell Dev Biol 2021;9:739392. [PMID: 34796174 DOI: 10.3389/fcell.2021.739392] [Reference Citation Analysis]
146 Duong LM, Cai H, Shrubsole MJ, Bailey CE, Idrees K, Shu XO. Outcomes of robotic-assisted liver surgery versus laparoscopic liver surgery for treatment of stage I hepatocellular carcinoma. Cancer 2021. [PMID: 34674225 DOI: 10.1002/cncr.33979] [Reference Citation Analysis]
147 Bu X, Ma L, Liu S, Wen D, Kan A, Xu Y, Lin X, Shi M. A novel qualitative signature based on lncRNA pairs for prognosis prediction in hepatocellular carcinoma. Cancer Cell Int 2022;22:95. [PMID: 35193591 DOI: 10.1186/s12935-022-02507-z] [Reference Citation Analysis]
148 Du J, Qian M, Yuan T, Zhang B, Chen X, An N, He Q, Yang B, Ye S, Zhu H. Fingolimod exerts in vitro anticancer activity against hepatocellular carcinoma cell lines via YAP/TAZ suppression. Acta Pharmaceutica 2022;72:427-36. [DOI: 10.2478/acph-2022-0029] [Reference Citation Analysis]
149 Lim Y, Ku NO. Revealing the Roles of Keratin 8/18-Associated Signaling Proteins Involved in the Development of Hepatocellular Carcinoma. Int J Mol Sci 2021;22:6401. [PMID: 34203895 DOI: 10.3390/ijms22126401] [Reference Citation Analysis]
150 Wei T, Zhang XF, Xue F, Bagante F, Ratti F, Marques HP, Silva S, Soubrane O, Lam V, Poultsides GA, Popescu I, Grigorie R, Alexandrescu S, Martel G, Workneh A, Guglielmi A, Hugh T, Aldrighetti L, Endo I, Pawlik TM. Multi-Institutional Development and External Validation of a Nomogram for Prediction of Extrahepatic Recurrence After Curative-Intent Resection for Hepatocellular Carcinoma. Ann Surg Oncol 2021. [PMID: 34019181 DOI: 10.1245/s10434-021-10142-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
151 Gupta S, Khan S, Kawka M, Gujjuri R, Chau I, Starling N, Cunningham D, Jiao LR, Gall T. Clinical utility of clonal origin determination in managing recurrent hepatocellular carcinoma. Expert Rev Gastroenterol Hepatol 2021;:1-9. [PMID: 34402366 DOI: 10.1080/17474124.2021.1967144] [Reference Citation Analysis]
152 Preel A, Hermida M, Allimant C, Assenat E, Guillot C, Gozzo C, Aho-Glele S, Pageaux GP, Cassinotto C, Guiu B. Uni-, Bi- or Trifocal Hepatocellular Carcinoma in Western Patients: Recurrence and Survival after Percutaneous Thermal Ablation. Cancers (Basel) 2021;13:2700. [PMID: 34070800 DOI: 10.3390/cancers13112700] [Reference Citation Analysis]
153 Mao J, Wang D, Long J, Yang X, Lin J, Song Y, Xie F, Xun Z, Wang Y, Wang Y, Li Y, Sun H, Xue J, Song Y, Zuo B, Zhang J, Bian J, Zhang T, Yang X, Zhang L, Sang X, Zhao H. Gut microbiome is associated with the clinical response to anti-PD-1 based immunotherapy in hepatobiliary cancers. J Immunother Cancer 2021;9:e003334. [PMID: 34873013 DOI: 10.1136/jitc-2021-003334] [Reference Citation Analysis]
154 Kong H, Ju E, Yi K, Xu W, Lao YH, Cheng D, Zhang Q, Tao Y, Li M, Ding J. Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma. Adv Sci (Weinh) 2021;:e2102051. [PMID: 34665528 DOI: 10.1002/advs.202102051] [Reference Citation Analysis]
155 Chen J, Lin Z, Liu L, Zhang R, Geng Y, Fan M, Zhu W, Lu M, Lu L, Jia H, Zhang J, Qin LX. GOLM1 exacerbates CD8+ T cell suppression in hepatocellular carcinoma by promoting exosomal PD-L1 transport into tumor-associated macrophages. Signal Transduct Target Ther 2021;6:397. [PMID: 34795203 DOI: 10.1038/s41392-021-00784-0] [Reference Citation Analysis]
156 Akuta N, Kawamura Y, Suzuki F, Kobayashi M, Arase Y, Saitoh S, Muraishi N, Fujiyama S, Sezaki H, Hosaka T, Kobayashi M, Suzuki Y, Ikeda K, Kumada H. Serum TERT C228T is an important predictor of non-viral liver cancer with fatty liver disease. Hepatol Int. [DOI: 10.1007/s12072-022-10313-y] [Reference Citation Analysis]
157 Liu S, Bu X, Kan A, Luo L, Xu Y, Chen H, Lin X, Lai Z, Wen D, Huang L, Shi M. SP1-induced lncRNA DUBR promotes stemness and oxaliplatin resistance of hepatocellular carcinoma via E2F1-CIP2A feedback. Cancer Lett 2021;528:16-30. [PMID: 34958891 DOI: 10.1016/j.canlet.2021.12.026] [Reference Citation Analysis]
158 Zhang K, Barry AE, Lamm R, Patel K, Schafer M, Dang H. The role of RNA binding proteins in hepatocellular carcinoma. Advanced Drug Delivery Reviews 2022. [DOI: 10.1016/j.addr.2022.114114] [Reference Citation Analysis]
159 Dai T, Ye L, Yu H, Li K, Li J, Liu R, Lu X, Deng M, Li R, Liu W, Yang Y, Wang G. Regulation Network and Prognostic Significance of Aldo-Keto Reductase (AKR) Superfamily Genes in Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:997-1021. [PMID: 34513744 DOI: 10.2147/JHC.S323743] [Reference Citation Analysis]
160 Guo Y, Wang J, Benedict B, Yang C, van Gemert F, Ma X, Gao D, Wang H, Zhang S, Lieftink C, Beijersbergen RL, Te Riele H, Qiao X, Gao Q, Sun C, Qin W, Bernards R, Wang C. Targeting CDC7 potentiates ATR-CHK1 signaling inhibition through induction of DNA replication stress in liver cancer. Genome Med 2021;13:166. [PMID: 34663432 DOI: 10.1186/s13073-021-00981-0] [Reference Citation Analysis]
161 Jung JM, Kim SH, Giang Phan VH, Thambi T, Lee DS. Therapeutic effects of boronate ester cross-linked injectable hydrogels for the treatment of hepatocellular carcinoma. Biomater Sci 2021;9:7275-86. [PMID: 34609388 DOI: 10.1039/d1bm00881a] [Reference Citation Analysis]
162 Wang H, Liu D, Wang C, Yu S, Jin G, Wang C, Zhang B, Zhang D, Shao D. Transarterial chemoembolization (TACE) plus apatinib-combined therapy versus TACE alone in the treatment of intermediate to advanced hepatocellular carcinoma patients: a real-world study. Clin Res Hepatol Gastroenterol 2022;:101869. [PMID: 35108656 DOI: 10.1016/j.clinre.2022.101869] [Reference Citation Analysis]
163 Tan J, Mathy RM, Chang DH, Tang T, Zhang ZS, Xiao YD. Combined transarterial iodized oil injection and computed tomography-guided thermal ablation for hepatocellular carcinoma: utility of the iodized oil retention pattern. Abdom Radiol (NY) 2021. [PMID: 34642785 DOI: 10.1007/s00261-021-03305-3] [Reference Citation Analysis]
164 Liu X, Wang C, Yang Q, Yuan Y, Sheng Y, Li D, Ojha SC, Sun C, Deng C. AC093797.1 as a Potential Biomarker to Indicate the Prognosis of Hepatocellular Carcinoma and Inhibits Cell Proliferation, Invasion, and Migration by Reprogramming Cell Metabolism and Extracellular Matrix Dynamics. Front Genet 2021;12:778742. [PMID: 34925460 DOI: 10.3389/fgene.2021.778742] [Reference Citation Analysis]
165 Llovet JM, Vogel A, Madoff DC, Finn RS, Ogasawara S, Ren Z, Mody K, Li JJ, Siegel AB, Dubrovsky L, Kudo M. Randomized Phase 3 LEAP-012 Study: Transarterial Chemoembolization With or Without Lenvatinib Plus Pembrolizumab for Intermediate-Stage Hepatocellular Carcinoma Not Amenable to Curative Treatment. Cardiovasc Intervent Radiol 2022. [PMID: 35119481 DOI: 10.1007/s00270-021-03031-9] [Reference Citation Analysis]
166 Zhang X, Ma YB, He XF, Li TZ, Geng CA, Su LH, Tang S, Gao Z, Chen JJ. Artemyrianosins A-J, cytotoxic germacrane-type sesquiterpene lactones from Artemisia myriantha. Nat Prod Bioprospect 2022;12:16. [PMID: 35491411 DOI: 10.1007/s13659-022-00340-5] [Reference Citation Analysis]
167 Xing M, Li J, Magistri P. A New Inflammation-Related Risk Model for Predicting Hepatocellular Carcinoma Prognosis. BioMed Research International 2022;2022:1-33. [DOI: 10.1155/2022/5396128] [Reference Citation Analysis]
168 Shao L, Yu X, Han Q, Zhang X, Lu N, Zhang C. Enhancing anti-tumor efficacy and immune memory by combining 3p-GPC-3 siRNA treatment with PD-1 blockade in hepatocellular carcinoma. OncoImmunology 2022;11:2010894. [DOI: 10.1080/2162402x.2021.2010894] [Reference Citation Analysis]
169 Krinsky G, Shanbhogue K. Proliferative versus Nonproliferative Hepatocellular Carcinoma: Clinical and Imaging Implications. Radiology 2021;300:583-5. [PMID: 34227887 DOI: 10.1148/radiol.2021211316] [Reference Citation Analysis]
170 Li YT, Wu HL, Liu CJ. Molecular Mechanisms and Animal Models of HBV-Related Hepatocellular Carcinoma: With Emphasis on Metastatic Tumor Antigen 1. Int J Mol Sci 2021;22:9380. [PMID: 34502289 DOI: 10.3390/ijms22179380] [Reference Citation Analysis]
171 Ahn JC, Qureshi TA, Singal AG, Li D, Yang JD. Deep learning in hepatocellular carcinoma: Current status and future perspectives. World J Hepatol 2021; 13(12): 2039-2051 [DOI: 10.4254/wjh.v13.i12.2039] [Reference Citation Analysis]
172 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
173 Kudo M. Changing the Treatment Paradigm for Hepatocellular Carcinoma Using Atezolizumab plus Bevacizumab Combination Therapy. Cancers (Basel) 2021;13:5475. [PMID: 34771637 DOI: 10.3390/cancers13215475] [Reference Citation Analysis]
174 Park Y, Han Y, Kim D, Cho S, Kim W, Hwang H, Lee HW, Han DH, Kim KS, Yun M, Lee M. Impact of Exogenous Treatment with Histidine on Hepatocellular Carcinoma Cells. Cancers 2022;14:1205. [DOI: 10.3390/cancers14051205] [Reference Citation Analysis]
175 Reinkens T, Stalke A, Huge N, Vajen B, Eilers M, Schäffer V, Dittrich-Breiholz O, Schlegelberger B, Illig T, Skawran B. Ago-RIP Sequencing Identifies New MicroRNA-449a-5p Target Genes Increasing Sorafenib Efficacy in Hepatocellular Carcinoma. J Cancer 2022;13:62-75. [PMID: 34976171 DOI: 10.7150/jca.66016] [Reference Citation Analysis]
176 Juratli MA, Struecker B, Katou S, Morguel MH, Pascher A. [Influence of molecular pathology on oncological surgery of liver and bile duct tumors]. Chirurg 2021;92:1003-10. [PMID: 34519849 DOI: 10.1007/s00104-021-01495-6] [Reference Citation Analysis]
177 Li Y, He X, Zhang X, Xu Y, Chen W, Liu X, Xu X. RMI2 is a prognostic biomarker and promotes tumor growth in hepatocellular carcinoma. Clin Exp Med 2021. [PMID: 34275027 DOI: 10.1007/s10238-021-00742-8] [Reference Citation Analysis]
178 Singal AG, Zhang E, Narasimman M, Rich NE, Waljee AK, Hoshida Y, Yang JD, Reig M, Cabibbo G, Nahon P, Parikh ND, Marrero JA. HCC Surveillance Improves Early Detection, Curative Treatment Receipt, and Survival in Patients with Cirrhosis: A Systematic Review and Meta-Analysis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.01.023] [Reference Citation Analysis]
179 Shimose S, Hiraoka A, Nakano M, Iwamoto H, Tanaka M, Tanaka T, Noguchi K, Aino H, Ogata K, Kajiwara M, Itano S, Yokokura Y, Yamaguchi T, Kawano H, Matsukuma N, Suga H, Niizeki T, Shirono T, Noda Y, Kamachi N, Okamura S, Kawaguchi T, Koga H, Torimura T. First-line sorafenib sequential therapy and liver disease etiology for unresectable hepatocellular carcinoma using inverse probability weighting: A multicenter retrospective study. Cancer Med 2021. [PMID: 34693661 DOI: 10.1002/cam4.4367] [Reference Citation Analysis]
180 Xu Y, Liao W, Luo Q, Yang D, Pan M. Histone Acetylation Regulator-Mediated Acetylation Patterns Define Tumor Malignant Pathways and Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol 2022;13:761046. [DOI: 10.3389/fimmu.2022.761046] [Reference Citation Analysis]
181 Deng X, Li X, Guo X, Lu Y, Xie Y, Huang X, Lin J, Tan W, Wang C. Myeloid-derived suppressor cells promote tumor growth and sorafenib resistance by inducing FGF1 upregulation and fibrosis. Neoplasia 2022;28:100788. [DOI: 10.1016/j.neo.2022.100788] [Reference Citation Analysis]
182 Zhang H, Zhang Y, Dong J, Zuo S, Meng G, Wu J, Wei J. Recombinant adenovirus expressing the fusion protein PD1PVR improves CD8+ T cell-mediated antitumor efficacy with long-term tumor-specific immune surveillance in hepatocellular carcinoma. Cell Oncol (Dordr) 2021. [PMID: 34491549 DOI: 10.1007/s13402-021-00633-w] [Reference Citation Analysis]
183 Dai T, Yang Q, Zhang Y, Ye L, Li H, Yi S, Liu W, Yang Y, Wang G. Camrelizumab (SHR-1210) treatment for recurrent hepatocellular carcinoma after liver transplant: A report of two cases. Liver Research 2021. [DOI: 10.1016/j.livres.2021.06.002] [Reference Citation Analysis]
184 Dai Y, Jiang H, Feng S, Xia Y, Li J, Zhao S, Wang D, Zeng X, Chen Y, Xin Y, Liu D. Noninvasive Imaging Evaluation Based on Computed Tomography of the Efficacy of Initial Transarterial Chemoembolization to Predict Outcome in Patients with Hepatocellular Carcinoma. JHC 2022;Volume 9:273-88. [DOI: 10.2147/jhc.s351077] [Reference Citation Analysis]
185 Wu H, Xu XF, Zhu JQ, Wang MD, Li C, Liang L, Xing H, Wu MC, Shen F, Huang DS, Yang T. Mesoporous Silica Nanoparticles for Potential Immunotherapy of Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:695635. [PMID: 34692650 DOI: 10.3389/fbioe.2021.695635] [Reference Citation Analysis]
186 Xu X, Wang B, Liu Y, Jing T, Xu G, Zhang L, Kun Jiao, Chen Z, Xiang L, Xu C, Yang Z, Liu Y. ETV4 potentiates nuclear YAP retention and activities to enhance the progression of hepatocellular carcinoma. Cancer Lett 2022;:215640. [PMID: 35296440 DOI: 10.1016/j.canlet.2022.215640] [Reference Citation Analysis]
187 Erdogan F, Radu TB, Orlova A, Qadree AK, de Araujo ED, Israelian J, Valent P, Mustjoki SM, Herling M, Moriggl R, Gunning PT. JAK-STAT core cancer pathway: An integrative cancer interactome analysis. J Cell Mol Med 2022. [PMID: 35229974 DOI: 10.1111/jcmm.17228] [Reference Citation Analysis]
188 Chen W, Gao C, Shen J, Yao L, Liang X, Chen Z. The expression and prognostic value of REXO4 in hepatocellular carcinoma. J Gastrointest Oncol 2021;12:1704-17. [PMID: 34532121 DOI: 10.21037/jgo-21-98] [Reference Citation Analysis]
189 Trézéguet V, Fatrouni H, Merched AJ. Immuno-Metabolic Modulation of Liver Oncogenesis by the Tryptophan Metabolism. Cells 2021;10:3469. [PMID: 34943977 DOI: 10.3390/cells10123469] [Reference Citation Analysis]
190 Zhang C, Liu S, Yang M. Hepatocellular Carcinoma and Obesity, Type 2 Diabetes Mellitus, Cardiovascular Disease: Causing Factors, Molecular Links, and Treatment Options. Front Endocrinol (Lausanne) 2021;12:808526. [PMID: 35002979 DOI: 10.3389/fendo.2021.808526] [Reference Citation Analysis]
191 Arshad R, Fatima I, Sargazi S, Rahdar A, Karamzadeh-Jahromi M, Pandey S, Díez-Pascual AM, Bilal M. Novel Perspectives towards RNA-Based Nano-Theranostic Approaches for Cancer Management. Nanomaterials (Basel) 2021;11:3330. [PMID: 34947679 DOI: 10.3390/nano11123330] [Reference Citation Analysis]
192 Xing J, Shen S, Dong Z, Hu X, Xu L, Liu X, Li Q, Zhang Y, Cui G, Yu Z. Analysis of Multi-Layer RNA Modification Patterns for the Characterization of Tumor Immune Microenvironment in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:761391. [PMID: 34858985 DOI: 10.3389/fcell.2021.761391] [Reference Citation Analysis]
193 Krstic J, Reinisch I, Schindlmaier K, Galhuber M, Riahi Z, Berger N, Kupper N, Moyschewitz E, Auer M, Michenthaler H, Nössing C, Depaoli MR, Ramadani-muja J, Usluer S, Stryeck S, Pichler M, Rinner B, Deutsch AJA, Reinisch A, Madl T, Chiozzi RZ, Heck AJR, Huch M, Malli R, Prokesch A. Fasting improves therapeutic response in hepatocellular carcinoma through p53-dependent metabolic synergism. Sci Adv 2022;8:eabh2635. [DOI: 10.1126/sciadv.abh2635] [Reference Citation Analysis]
194 Quintavalle C, Meyer-Schaller N, Roessler S, Calabrese D, Marone R, Riedl T, Picco-Rey S, Panagiotou OA, Uzun S, Piscuoglio S, Boldanova T, Bian CB, Semela D, Jochum W, Cathomas G, Mertz KD, Diebold J, Mazzucchelli L, Koelzer VH, Weber A, Decaens T, Terracciano LM, Heikenwalder M, Hoshida Y, Andersen JB, Thorgeirsson SS, Matter MS. miR-579-3p Controls Hepatocellular Carcinoma Formation by Regulating the Phosphoinositide 3-Kinase-Protein Kinase B Pathway in Chronically Inflamed Liver. Hepatol Commun 2022. [PMID: 35132819 DOI: 10.1002/hep4.1894] [Reference Citation Analysis]
195 Shen Y, Liu J, Han Z, Jiang W, Cui H, Xun Y. Risk prediction models for hepatocellular carcinoma in chronic hepatitis B patients on antiviral therapy: a meta-analysis. Clin Res Hepatol Gastroenterol 2022;:101930. [PMID: 35460902 DOI: 10.1016/j.clinre.2022.101930] [Reference Citation Analysis]
196 Oura K, Morishita A, Tani J, Masaki T. Tumor Immune Microenvironment and Immunosuppressive Therapy in Hepatocellular Carcinoma: A Review. Int J Mol Sci 2021;22:5801. [PMID: 34071550 DOI: 10.3390/ijms22115801] [Reference Citation Analysis]
197 Unfried JP, Sangro P, Prats-Mari L, Sangro B, Fortes P. The Landscape of lncRNAs in Hepatocellular Carcinoma: A Translational Perspective. Cancers (Basel) 2021;13:2651. [PMID: 34071216 DOI: 10.3390/cancers13112651] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
198 Liu J, Sauer MA, Hussein SG, Yang J, Tenen DG, Chai L. SALL4 and microRNA: The Role of Let-7. Genes (Basel) 2021;12:1301. [PMID: 34573282 DOI: 10.3390/genes12091301] [Reference Citation Analysis]
199 Huang S, Zhang J, Lai X, Zhuang L, Wu J. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients. Front Mol Biosci 2021;8:781307. [PMID: 35004851 DOI: 10.3389/fmolb.2021.781307] [Reference Citation Analysis]
200 Wang R, Fan H, Sun M, Lv Z, Yi W. Roles of BMI1 in the Initiation, Progression, and Treatment of Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338211070689. [PMID: 35072573 DOI: 10.1177/15330338211070689] [Reference Citation Analysis]
201 Meng T, Wang Q, Yang Y, Ren Y, Shi Y. Construction of a Necroptosis-Related miRNA Signature for Predicting the Prognosis of Patients With Hepatocellular Carcinoma. Front Genet 2022;13:825261. [DOI: 10.3389/fgene.2022.825261] [Reference Citation Analysis]
202 Fu XW, Song CQ. Identification and Validation of Pyroptosis-Related Gene Signature to Predict Prognosis and Reveal Immune Infiltration in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:748039. [PMID: 34820376 DOI: 10.3389/fcell.2021.748039] [Reference Citation Analysis]
203 Zahra FT, Sajib MS, Mikelis CM. Role of bFGF in Acquired Resistance upon Anti-VEGF Therapy in Cancer. Cancers (Basel) 2021;13:1422. [PMID: 33804681 DOI: 10.3390/cancers13061422] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
204 Vardar BU, Meram E, Karaoglu K, Liang M, Yu M, Laeseke P, Ozkan OS. Radioembolization Followed by Transarterial Chemoembolization in Hepatocellular Carcinoma. Cureus. [DOI: 10.7759/cureus.23783] [Reference Citation Analysis]
205 Wong AM, Ding X, Wong AM, Xu M, Zhang L, Leung HH, Chan AW, Song QX, Kwong J, Chan LK, Man M, He M, Chen J, Zhang Z, You W, Lau C, Yu A, Wei Y, Yuan Y, Lai PB, Zhao J, Man K, Yu J, Kahn M, Wong N. Unique molecular characteristics of NAFLD-associated liver cancer accentuate β-catenin/TNFRSF19-mediated immune evasion. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.015] [Reference Citation Analysis]
206 Wu J, Ding W, Wang Y, Liu S, Zhang X, Yang Q, Cai W, Yu X, Liu F, Kong D, Zhong H, Yu J, Liang P. Radiomics analysis of ultrasound to predict recurrence of hepatocellular carcinoma after microwave ablation. International Journal of Hyperthermia 2022;39:595-604. [DOI: 10.1080/02656736.2022.2062463] [Reference Citation Analysis]
207 Xia F, Ndhlovu E, Zhang M, Chen X, Zhang B, Zhu P. Ruptured Hepatocellular Carcinoma: Current Status of Research. Front Oncol 2022;12:848903. [DOI: 10.3389/fonc.2022.848903] [Reference Citation Analysis]
208 Zeng S, Schnabl B. Roles for the mycobiome in liver disease. Liver Int 2022. [PMID: 34995410 DOI: 10.1111/liv.15160] [Reference Citation Analysis]
209 Zhang BH, Cai YS, Jiang L, Yang JY. Donafenib as a first-line monotherapy for advanced hepatocellular carcinoma. Hepatobiliary Surg Nutr 2021;10:737-40. [PMID: 34760990 DOI: 10.21037/hbsn-21-304] [Reference Citation Analysis]
210 Yang Y, Li J, Tang M, Nie B, Huang W. Decaprenyl Diphosphate Synthase Subunit 1 (PDSS1): A Potential Prognostic Biomarker and Immunotherapy-Target for Hepatocellular Carcinoma. CMAR 2022;Volume 14:1627-39. [DOI: 10.2147/cmar.s364346] [Reference Citation Analysis]
211 Kaps L, Huppertsberg A, Choteschovsky N, Klefenz A, Durak F, Schrörs B, Diken M, Eichler E, Rosigkeit S, Schmitt S, Leps C, Schulze A, Foerster F, Bockamp E, De Geest BG, Koynov K, Räder HJ, Tenzer S, Marini F, Schuppan D, Nuhn L. pH-degradable, bisphosphonate-loaded nanogels attenuate liver fibrosis by repolarization of M2-type macrophages. Proc Natl Acad Sci U S A 2022;119:e2122310119. [PMID: 35290110 DOI: 10.1073/pnas.2122310119] [Reference Citation Analysis]
212 Lu LG, Zhou ZL, Wang XY, Liu BY, Lu JY, Liu S, Zhang GB, Zhan MX, Chen Y. PD-L1 blockade liberates intrinsic antitumourigenic properties of glycolytic macrophages in hepatocellular carcinoma. Gut 2022:gutjnl-2021-326350. [PMID: 35173040 DOI: 10.1136/gutjnl-2021-326350] [Reference Citation Analysis]
213 Rimini M, Kudo M, Tada T, Shigeo S, Kang W, Suda G, Jefremow A, Burgio V, Iavarone M, Tortora R, Marra F, Lonardi S, Tamburini E, Piscaglia F, Masi G, Cabibbo G, Foschi FG, Silletta M, Kumada T, Iwamoto H, Aoki T, Goh MJ, Sakamoto N, Siebler J, Hiraoka A, Niizeki T, Ueshima K, Sho T, Atsukawa M, Hirooka M, Tsuji K, Ishikawa T, Takaguchi K, Kariyama K, Itobayashi E, Tajiri K, Shimada N, Shibata H, Ochi H, Yasuda S, Toyoda H, Fukunishi S, Ohama H, Kawata K, Tani J, Nakamura S, Nouso K, Tsutsui A, Nagano T, Takaaki T, Itokawa N, Okubo T, Arai T, Imai M, Joko K, Koizumi Y, Hiasa Y, Cucchetti A, Ratti F, Aldrighetti L, Cascinu S, Casadei-Gardini A. Nonalcoholic steatohepatitis in hepatocarcinoma: new insights about its prognostic role in patients treated with lenvatinib. ESMO Open 2021;6:100330. [PMID: 34847382 DOI: 10.1016/j.esmoop.2021.100330] [Reference Citation Analysis]
214 Qayum K, Kar I, Rashid U, Nawaz G, Krishnakumar P, Sudarshan V, Syed A. Effects of surgery, chemotherapy, and radiation on hepatocellular carcinoma patients: A SEER-based study. Ann Med Surg (Lond) 2021;69:102782. [PMID: 34522376 DOI: 10.1016/j.amsu.2021.102782] [Reference Citation Analysis]
215 Batur T, Argundogan A, Keles U, Mutlu Z, Alotaibi H, Senturk S, Ozturk M. AXL Knock-Out in SNU475 Hepatocellular Carcinoma Cells Provides Evidence for Lethal Effect Associated with G2 Arrest and Polyploidization. Int J Mol Sci 2021;22:13247. [PMID: 34948046 DOI: 10.3390/ijms222413247] [Reference Citation Analysis]
216 Ji C, Liu Z, Wang Y, Ni J, Zheng C. GATNNCDA: A Method Based on Graph Attention Network and Multi-Layer Neural Network for Predicting circRNA-Disease Associations. Int J Mol Sci 2021;22:8505. [PMID: 34445212 DOI: 10.3390/ijms22168505] [Reference Citation Analysis]
217 Gu X, Zhou H, Chu Q, Zheng Q, Wang J, Zhu H. Uncovering the Association Between m5C Regulator-Mediated Methylation Modification Patterns and Tumour Microenvironment Infiltration Characteristics in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:727935. [PMID: 34589490 DOI: 10.3389/fcell.2021.727935] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
218 Tian Z, Zhao J, Wang Y. The prognostic value of TPM1-4 in hepatocellular carcinoma. Cancer Med 2021. [PMID: 34850589 DOI: 10.1002/cam4.4453] [Reference Citation Analysis]
219 Shuyao W, Mingyang B, Feifei M, Xiaoqin H. CK19 Predicts Recurrence and Prognosis of HBV Positive HCC. J Gastrointest Surg 2021. [PMID: 34506016 DOI: 10.1007/s11605-021-05107-w] [Reference Citation Analysis]
220 Yang J, Wang J, Li H, Gao S, Fan Y, Wang K. IL-6 Promoter Hypomethylation Acts As a Diagnostic Biomarker in Hepatitis B Virus-Associated Hepatocellular Carcinoma. Front Oncol 2022;12:746643. [DOI: 10.3389/fonc.2022.746643] [Reference Citation Analysis]
221 Pezzuto F, Izzo F, De Luca P, Biffali E, Buonaguro L, Tatangelo F, Buonaguro FM, Tornesello ML. Clinical Significance of Telomerase Reverse-Transcriptase Promoter Mutations in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3771. [PMID: 34359670 DOI: 10.3390/cancers13153771] [Reference Citation Analysis]
222 Singal AG, Reddy S, Radadiya Aka Patel H, Villarreal D, Khan A, Liu Y, Cerda V, Rich NE, Murphy CC, Tiro JA, Kramer JR, Hernaez R. Multicenter Randomized Clinical Trial of a Mailed Outreach Strategy for Hepatocellular Carcinoma Surveillance. Clin Gastroenterol Hepatol 2021:S1542-3565(21)01309-4. [PMID: 34902568 DOI: 10.1016/j.cgh.2021.12.014] [Reference Citation Analysis]
223 Sánchez PS, Rigual MDM, Djouder N. Inflammatory and Non-Inflammatory Mechanisms Controlling Cirrhosis Development. Cancers (Basel) 2021;13:5045. [PMID: 34680192 DOI: 10.3390/cancers13205045] [Reference Citation Analysis]
224 Tan J, Tang T, Zhao W, Zhang ZS, Xiao YD. Initial Incomplete Thermal Ablation Is Associated With a High Risk of Tumor Progression in Patients With Hepatocellular Carcinoma. Front Oncol 2021;11:760173. [PMID: 34733792 DOI: 10.3389/fonc.2021.760173] [Reference Citation Analysis]
225 Talebi AS, Rajabi H, Watabe H. Role of nanoparticles in transarterial radioembolization with glass microspheres. Ann Nucl Med 2022. [PMID: 35199286 DOI: 10.1007/s12149-022-01727-7] [Reference Citation Analysis]
226 Pan L, Feng F, Wu J, Li L, Xu H, Yang L, Xu K, Wang C. Diosmetin inhibits cell growth and proliferation by regulating the cell cycle and lipid metabolism pathway in hepatocellular carcinoma. Food Funct 2021. [PMID: 34755740 DOI: 10.1039/d1fo02111g] [Reference Citation Analysis]
227 Busche S, John K, Wandrer F, Vondran FWR, Lehmann U, Wedemeyer H, Essmann F, Schulze-Osthoff K, Bantel H. BH3-only protein expression determines hepatocellular carcinoma response to sorafenib-based treatment. Cell Death Dis 2021;12:736. [PMID: 34312366 DOI: 10.1038/s41419-021-04020-z] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
228 Arvanitakis K, Mitroulis I, Germanidis G. Tumor-Associated Neutrophils in Hepatocellular Carcinoma Pathogenesis, Prognosis, and Therapy. Cancers (Basel) 2021;13:2899. [PMID: 34200529 DOI: 10.3390/cancers13122899] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
229 Wabitsch S, Mccallen JD, Kamenyeva O, Ruf B, Mcvey JC, Kabat J, Walz JS, Rotman Y, Bauer KC, Craig AJ, Pouzolles M, Phadke I, Catania V, Green BL, Fu C, Diggs LP, Heinrich B, Wang XW, Ma C, Greten TF. Metformin treatment rescues CD8+ T cell response to immune checkpoint inhibitor therapy in mice with NAFLD. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.03.010] [Reference Citation Analysis]
230 Hernández-Alvarez MI, Zorzano A. Mitochondrial Dynamics and Liver Cancer. Cancers (Basel) 2021;13:2571. [PMID: 34073868 DOI: 10.3390/cancers13112571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
231 Yang X, Sun J, Wen B, Wang Y, Zhang M, Chen W, Zhao W, He C, Zhong X, Liu Y, Li T, Sun H, He S. Biejiajian Pill Promotes the Infiltration of CD8+ T Cells in Hepatocellular Carcinoma by Regulating the Expression of CCL5. Front Pharmacol 2021;12:771046. [PMID: 34899325 DOI: 10.3389/fphar.2021.771046] [Reference Citation Analysis]
232 Haber PK, Puigvehí M, Castet F, Lourdusamy V, Montal R, Tabrizian P, Buckstein M, Kim E, Villanueva A, Schwartz M, Llovet JM. Evidence-Based Management of Hepatocellular Carcinoma: Systematic Review and Meta-analysis of Randomized Controlled Trials (2002-2020). Gastroenterology 2021;161:879-98. [PMID: 34126063 DOI: 10.1053/j.gastro.2021.06.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
233 Liu Y, Cheng DH, Lai KD, Su H, Lu GS, Wang L, Lv JH. Ventilagolin Suppresses Migration, Invasion and Epithelial-Mesenchymal Transition of Hepatocellular Carcinoma Cells by Downregulating Pim-1. Drug Des Devel Ther 2021;15:4885-99. [PMID: 34880599 DOI: 10.2147/DDDT.S327270] [Reference Citation Analysis]
234 Deng W, Chen F, Zhou Z, Huang Y, Lin J, Zhang F, Xiao G, Liu C, Liu C, Xu L. Hepatitis B Virus Promotes Hepatocellular Carcinoma Progression Synergistically With Hepatic Stellate Cells via Facilitating the Expression and Secretion of ENPP2. Front Mol Biosci 2021;8:745990. [PMID: 34805271 DOI: 10.3389/fmolb.2021.745990] [Reference Citation Analysis]
235 Araujo OC, de Paula VS, do Ó KM, Villela-Nogueira CA, Araujo NM. Association of Polymorphisms in the Glutathione S-Transferase Theta-1 Gene with Cirrhosis and Hepatocellular Carcinoma in Brazilian Patients with Chronic Hepatitis C. Vaccines (Basel) 2021;9:831. [PMID: 34451956 DOI: 10.3390/vaccines9080831] [Reference Citation Analysis]
236 Gonzalez-Sanchez E, Vaquero J, Férnandez-Barrena MG, Lasarte JJ, Avila MA, Sarobe P, Reig M, Calvo M, Fabregat I. The TGF-β Pathway: A Pharmacological Target in Hepatocellular Carcinoma? Cancers (Basel) 2021;13:3248. [PMID: 34209646 DOI: 10.3390/cancers13133248] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
237 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
238 Fan X, Deng J, Shi T, Wen H, Li J, Liang Z, Lei F, Liu D, Zhang H, Liang Y, Hao X, Wang Z. Design, synthesis and bioactivity study of evodiamine derivatives as multifunctional agents for the treatment of hepatocellular carcinoma. Bioorg Chem 2021;114:105154. [PMID: 34378540 DOI: 10.1016/j.bioorg.2021.105154] [Reference Citation Analysis]
239 Vulf M, Shunkina D, Komar A, Bograya M, Zatolokin P, Kirienkova E, Gazatova N, Kozlov I, Litvinova L. Analysis of miRNAs Profiles in Serum of Patients With Steatosis and Steatohepatitis. Front Cell Dev Biol 2021;9:736677. [PMID: 34568346 DOI: 10.3389/fcell.2021.736677] [Reference Citation Analysis]
240 Paul B, Lewinska M, Andersen JB. Lipid alterations in chronic liver disease and liver cancer. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100479] [Reference Citation Analysis]
241 Li Q, Xu H, Sui C, Zhang H. Impact of metformin use on risk and mortality of hepatocellular carcinoma in diabetes mellitus. Clin Res Hepatol Gastroenterol 2021;:101781. [PMID: 34332136 DOI: 10.1016/j.clinre.2021.101781] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
242 Jiang H, Song B, Qin Y, Konanur M, Wu Y, McInnes MDF, Lafata KJ, Bashir MR. Modifying LI-RADS on Gadoxetate Disodium-Enhanced MRI: A Secondary Analysis of a Prospective Observational Study. J Magn Reson Imaging 2022. [PMID: 34994029 DOI: 10.1002/jmri.28056] [Reference Citation Analysis]
243 Li W, Han L, Xiao B, Li X, Ye Z. A Predictive Nomogram of Early Recurrence for Patients with AFP-Negative Hepatocellular Carcinoma Underwent Curative Resection. Diagnostics 2022;12:1073. [DOI: 10.3390/diagnostics12051073] [Reference Citation Analysis]
244 Karamali N, Ebrahimnezhad S, Khaleghi Moghadam R, Daneshfar N, Rezaiemanesh A. HRD1 in human malignant neoplasms: Molecular mechanisms and novel therapeutic strategy for cancer. Life Sci 2022;301:120620. [PMID: 35533759 DOI: 10.1016/j.lfs.2022.120620] [Reference Citation Analysis]
245 Geh D, Leslie J, Rumney R, Reeves HL, Bird TG, Mann DA. Neutrophils as potential therapeutic targets in hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 2022. [PMID: 35022608 DOI: 10.1038/s41575-021-00568-5] [Reference Citation Analysis]
246 Harkus U, Wankell M, Palamuthusingam P, Mcfarlane C, Hebbard L. Immune checkpoint inhibitors in HCC: cellular, molecular and systemic data. Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.01.005] [Reference Citation Analysis]
247 Melendez-Torres J, Singal AG. Early detection of hepatocellular carcinoma: roadmap for improvement. Expert Rev Anticancer Ther 2022. [PMID: 35514249 DOI: 10.1080/14737140.2022.2074404] [Reference Citation Analysis]
248 Sun Z, Shi Z, Xin Y, Zhao S, Jiang H, Wang D, Zhang L, Wang Z, Dai Y, Jiang H. Artificial Intelligent Multi-Modal Point-of-Care System for Predicting Response of Transarterial Chemoembolization in Hepatocellular Carcinoma. Front Bioeng Biotechnol 2021;9:761548. [PMID: 34869272 DOI: 10.3389/fbioe.2021.761548] [Reference Citation Analysis]
249 Gabbia D, Cannella L, De Martin S. The Role of Oxidative Stress in NAFLD-NASH-HCC Transition-Focus on NADPH Oxidases. Biomedicines 2021;9:687. [PMID: 34204571 DOI: 10.3390/biomedicines9060687] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
250 Fan PL, Chu J, Wang Q, Wang C. The clinical value of dual-energy computed tomography and diffusion-weighted imaging in the context of liver cancer: A narrative review. J Clin Ultrasound 2022. [PMID: 35338779 DOI: 10.1002/jcu.23197] [Reference Citation Analysis]
251 Lin C, Kuo JC, Li D, Koenig AB, Pan A, Yan P, Bai X, Lee RJ, Ghoshal K. AZD5153, a Bivalent BRD4 Inhibitor, Suppresses Hepatocarcinogenesis by Altering BRD4 Chromosomal Landscape and Modulating the Transcriptome of HCC Cells. Front Cell Dev Biol 2022;10:853652. [DOI: 10.3389/fcell.2022.853652] [Reference Citation Analysis]
252 Bai XM, Yang W. Radiofrequency ablation of hepatocellular carcinoma: Prognostic factors and recent advances. Shijie Huaren Xiaohua Zazhi 2021; 29(13): 677-683 [DOI: 10.11569/wcjd.v29.i13.677] [Reference Citation Analysis]
253 D'Alessio A, Cammarota A, Zanuso V, Pressiani T, Personeni N, Rimassa L. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma. Expert Rev Anticancer Ther 2021;21:927-39. [PMID: 34167423 DOI: 10.1080/14737140.2021.1948329] [Reference Citation Analysis]
254 Fondevila F, Fernández-Palanca P, Méndez-Blanco C, Payo-Serafín T, Lozano E, Marin JJG, González-Gallego J, Mauriz JL. Association of FOXO3 Expression with Tumor Pathogenesis, Prognosis and Clinicopathological Features in Hepatocellular Carcinoma: A Systematic Review with Meta-Analysis. Cancers (Basel) 2021;13:5349. [PMID: 34771514 DOI: 10.3390/cancers13215349] [Reference Citation Analysis]
255 Lin CS, Liang Y, Su SG, Zheng YL, Yang X, Jiang N, Fu L, Zhou J, Zhang Y, Deng R, Wang CH, Lu SX, Huang YH, Liu LL, Zhang C, Yun JP. Nucleoporin 93 mediates β-catenin nuclear import to promote hepatocellular carcinoma progression and metastasis. Cancer Lett 2021;526:236-47. [PMID: 34767927 DOI: 10.1016/j.canlet.2021.11.001] [Reference Citation Analysis]
256 D'Ambrosio R, Degasperi E, Lampertico P. Predicting Hepatocellular Carcinoma Risk in Patients with Chronic HCV Infection and a Sustained Virological Response to Direct-Acting Antivirals. J Hepatocell Carcinoma 2021;8:713-39. [PMID: 34235108 DOI: 10.2147/JHC.S292139] [Reference Citation Analysis]
257 Yu HM, Wang K, Feng JK, Lu L, Qin YC, Cheng YQ, Guo WX, Shi J, Cong WM, Lau WY, Dong H, Cheng SQ. Image-matching digital macro-slide-a novel pathological examination method for microvascular invasion detection in hepatocellular carcinoma. Hepatol Int 2022. [PMID: 35294742 DOI: 10.1007/s12072-022-10307-w] [Reference Citation Analysis]
258 Rizzo A, Dadduzio V, Ricci AD, Massari F, Di Federico A, Gadaleta-Caldarola G, Brandi G. Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma? Expert Opin Investig Drugs 2021;:1-8. [PMID: 34167433 DOI: 10.1080/13543784.2021.1948532] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
259 Zhang Y, Zhang Y, Shi X, Li J, Wang L, Xie C, Wang Y. Chenodeoxycholic Acid Enhances the Effect of Sorafenib in Inhibiting HepG2 Cell Growth Through EGFR/Stat3 Pathway. Front Oncol 2022;12:836333. [DOI: 10.3389/fonc.2022.836333] [Reference Citation Analysis]
260 Zhou S, Li Y, Gao J, Wang Y, Ma X, Ding H, Li X, Sun S. Novel protein kinase C phosphorylated kinase inhibitor-matrine suppresses replication of hepatitis B virus via modulating the mitogen-activated protein kinase signal. Bioengineered 2022;13:2851-65. [PMID: 35037840 DOI: 10.1080/21655979.2021.2024957] [Reference Citation Analysis]
261 Xu Y, Tian H, Luan CG, Sun K, Bao PJ, Zhang HY, Zhang N. Telocytes promote hepatocellular carcinoma by activating the ERK signaling pathway and miR-942-3p/MMP9 axis. Cell Death Discov 2021;7:209. [PMID: 34376644 DOI: 10.1038/s41420-021-00592-z] [Reference Citation Analysis]
262 Ho C, Lin K, Shen R, Gu D, Lee S, Su W, Jou Y. Prognostic comparative genes predict targets for sorafenib combination therapies in hepatocellular carcinoma. Computational and Structural Biotechnology Journal 2022. [DOI: 10.1016/j.csbj.2022.04.008] [Reference Citation Analysis]
263 Riquelme I, Pérez-Moreno P, Letelier P, Brebi P, Roa JC. The Emerging Role of PIWI-Interacting RNAs (piRNAs) in Gastrointestinal Cancers: An Updated Perspective. Cancers (Basel) 2021;14:202. [PMID: 35008366 DOI: 10.3390/cancers14010202] [Reference Citation Analysis]
264 Wu H, Zhu JQ, Xu XF, Xing H, Wang MD, Liang L, Li C, Jia HD, Shen F, Huang DS, Yang T. Biointerfacing Antagonizing T-Cell Inhibitory Nanoparticles Potentiate Hepatocellular Carcinoma Checkpoint Blockade Therapy. Small 2021;:e2105237. [PMID: 34791793 DOI: 10.1002/smll.202105237] [Reference Citation Analysis]
265 Qin L, Huang D, Huang J, Qin F, Huang H. Integrated Analysis and Finding Reveal Anti-Liver Cancer Targets and Mechanisms of Pachyman (Poria cocos Polysaccharides). Front Pharmacol 2021;12:742349. [PMID: 34603055 DOI: 10.3389/fphar.2021.742349] [Reference Citation Analysis]
266 Wang HW, Chuang PH, Su WP, Kao JT, Hsu WF, Lin CC, Huang GT, Lin JT, Lai HC, Peng CY. On-Treatment Albumin-Bilirubin Grade: Predictor of Response and Outcome of Sorafenib-Regorafenib Sequential Therapy in Patients with Unresectable Hepatocellular Carcinoma. Cancers (Basel) 2021;13:3758. [PMID: 34359658 DOI: 10.3390/cancers13153758] [Reference Citation Analysis]
267 Ma Q, Xu Q, Zhao J, Zhang W, Wang Q, Fang J, Lu Z, Liu J, Ma L. Coupling HDAC4 with transcriptional factor MEF2D abrogates SPRY4-mediated suppression of ERK activation and elicits hepatocellular carcinoma drug resistance. Cancer Lett 2021;520:243-54. [PMID: 34339801 DOI: 10.1016/j.canlet.2021.07.049] [Reference Citation Analysis]
268 Yim SY, Lee JS. An Overview of the Genomic Characterization of Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:1077-88. [PMID: 34522690 DOI: 10.2147/JHC.S270533] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
269 Liu Z, Li M, Jia Y, Wang S, Zheng L, Wang C, Chen L. A randomized clinical trial of guided self-help intervention based on mindfulness for patients with hepatocellular carcinoma: effects and mechanisms. Jpn J Clin Oncol 2022:hyab198. [PMID: 35088079 DOI: 10.1093/jjco/hyab198] [Reference Citation Analysis]
270 Xu H, Wang L. The Role of Notch Signaling Pathway in Non-Alcoholic Fatty Liver Disease. Front Mol Biosci 2021;8:792667. [PMID: 34901163 DOI: 10.3389/fmolb.2021.792667] [Reference Citation Analysis]
271 Fondevila F, Méndez-Blanco C, Fernández-Palanca P, Payo-Serafín T, van Pelt J, Verslype C, González-Gallego J, Mauriz JL. Autophagy-Related Chemoprotection against Sorafenib in Human Hepatocarcinoma: Role of FOXO3 Upregulation and Modulation by Regorafenib. Int J Mol Sci 2021;22:11770. [PMID: 34769197 DOI: 10.3390/ijms222111770] [Reference Citation Analysis]
272 Wei T, Lin R, Fu X, Lu Y, Zhang W, Li Z, Zhang J, Wang H. Epigenetic regulation of the DNMT1/MT1G/KLF4/CA9 axis synergizes the anticancer effects of sorafenib in hepatocellular carcinoma. Pharmacological Research 2022. [DOI: 10.1016/j.phrs.2022.106244] [Reference Citation Analysis]
273 Hui RW, Chan AC, Lo G, Lo R, Chan C, Kotewall CN, Mak L, She W, Au K, Ai V, Fung J, Yuen M, Seto W. Magnetic resonance elastography and proton density fat fraction predict adverse outcomes in hepatocellular carcinoma. Hepatol Int. [DOI: 10.1007/s12072-022-10305-y] [Reference Citation Analysis]
274 Castelli S, Desideri E, Rosa Ciriolo M. ROS-mediated activation of p38 protects hepatocellular carcinoma cells from caspase-independent death elicited by lysosomal damage. Biochemical Pharmacology 2022. [DOI: 10.1016/j.bcp.2022.114983] [Reference Citation Analysis]
275 Seryakov A, Magomedova Z, Suntsova M, Prokofieva A, Rabushko E, Glusker A, Makovskaia L, Zolotovskaia M, Buzdin A, Sorokin M. RNA Sequencing for Personalized Treatment of Metastatic Leiomyosarcoma: Case Report. Front Oncol 2021;11:666001. [PMID: 34527573 DOI: 10.3389/fonc.2021.666001] [Reference Citation Analysis]
276 Cai J, Zhao J, Liu D, Xie H, Qi H, Ma J, Sun Z, Zhao H. Efficacy and Safety of Central Memory T Cells Combined With Adjuvant Therapy to Prevent Recurrence of Hepatocellular Carcinoma With Microvascular Invasion: A Pilot Study. Front Oncol 2021;11:781029. [PMID: 34926296 DOI: 10.3389/fonc.2021.781029] [Reference Citation Analysis]
277 Fu K, Wang C, Ma C, Zhou H, Li Y. The Potential Application of Chinese Medicine in Liver Diseases: A New Opportunity. Front Pharmacol 2021;12:771459. [PMID: 34803712 DOI: 10.3389/fphar.2021.771459] [Reference Citation Analysis]
278 Wang Z, Zhang S. Multi-omic analyses of hepatocellular carcinoma to determine immunological characteristics and key nodes in gene-expression network. Biosci Rep 2021;41:BSR20211241. [PMID: 34212175 DOI: 10.1042/BSR20211241] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
279 Hedrich V, Breitenecker K, Djerlek L, Ortmayr G, Mikulits W. Intrinsic and Extrinsic Control of Hepatocellular Carcinoma by TAM Receptors. Cancers (Basel) 2021;13:5448. [PMID: 34771611 DOI: 10.3390/cancers13215448] [Reference Citation Analysis]
280 Birgin E, Kaslow SR, Hetjens S, Correa-Gallego C, Rahbari NN. Minimally Invasive versus Open Liver Resection for Stage I/II Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4800. [PMID: 34638285 DOI: 10.3390/cancers13194800] [Reference Citation Analysis]
281 Lei P, Chen H, Feng C, Yuan X, Xiong Z, Liu Y, Liao W. Noninvasive Visualization of Sub-5 mm Orthotopic Hepatic Tumors by a Nanoprobe-Mediated Positive and Reverse Contrast-Balanced Imaging Strategy. ACS Nano 2022. [PMID: 35005889 DOI: 10.1021/acsnano.1c08477] [Reference Citation Analysis]
282 Tohme S, Yazdani HO, Rahman A, Handu S, Khan S, Wilson T, Geller DA, Simmons RL, Molinari M, Kaltenmeier C. The Use of Machine Learning to Create a Risk Score to Predict Survival in Patients with Hepatocellular Carcinoma: A TCGA Cohort Analysis. Can J Gastroenterol Hepatol 2021;2021:5212953. [PMID: 34888264 DOI: 10.1155/2021/5212953] [Reference Citation Analysis]
283 Wu CC, Wang MR. Effects of Buffer Concentration on the Sensitivity of Silicon Nanobelt Field-Effect Transistor Sensors. Sensors (Basel) 2021;21:4904. [PMID: 34300642 DOI: 10.3390/s21144904] [Reference Citation Analysis]
284 Qi J, Wang W, Tang Y, Lou S, Wang J, Yuan T, He Q, Yang B, Zhu H, Cui S. Discovery of Novel Indazoles as Potent and Selective PI3Kδ Inhibitors with High Efficacy for Treatment of Hepatocellular Carcinoma. J Med Chem 2022. [PMID: 35191698 DOI: 10.1021/acs.jmedchem.1c01520] [Reference Citation Analysis]
285 Zhang S, Xu L, Feng J, Tan D, Zhu Y, Hou J, Li W, Lv K, Wang W, Jiang L, Jiao M, Guo H. ASF1B is a Promising Prognostic Biomarker and Correlates With Immunotherapy Efficacy in Hepatocellular Carcinoma. Front Genet 2022;13:842351. [DOI: 10.3389/fgene.2022.842351] [Reference Citation Analysis]
286 Montironi C, Castet F, Haber PK, Pinyol R, Torres-Martin M, Torrens Fontanals L, Mesropian A, Wang H, Puigvehi M, Maeda M, Leow WQ, Harrod E, Taik P, Chinburen J, Taivanbaatar E, Chinbold E, Solé Arqués M, Donovan M, Thung S, Neely J, Mazzaferro V, Anderson J, Roayaie S, Schwartz M, Villanueva A, Friedman SL, Uzilov A, Sia D, Llovet JM. Inflamed and non-inflamed classes of HCC: a revised immunogenomic classification. Gut 2022:gutjnl-2021-325918. [PMID: 35197323 DOI: 10.1136/gutjnl-2021-325918] [Reference Citation Analysis]
287 Deng X, Luo T, Li Z, Wen H, Zhang H, Yang X, Lei F, Liu D, Shi T, Zhao Q, Wang Z. Design, synthesis and anti-hepatocellular carcinoma activity of 3-arylisoquinoline alkaloids. Eur J Med Chem 2022;228:113985. [PMID: 34802836 DOI: 10.1016/j.ejmech.2021.113985] [Reference Citation Analysis]
288 Jacquelot N, Seillet C, Souza-Fonseca-Guimaraes F, Sacher AG, Belz GT, Ohashi PS. Natural Killer Cells and Type 1 Innate Lymphoid Cells in Hepatocellular Carcinoma: Current Knowledge and Future Perspectives. Int J Mol Sci 2021;22:9044. [PMID: 34445750 DOI: 10.3390/ijms22169044] [Reference Citation Analysis]
289 Huang Q, Wu D, Zhao J, Yan Z, Chen L, Guo S, Wang D, Yuan C, Wang Y, Liu X, Xing J. TFAM loss induces nuclear actin assembly upon mDia2 malonylation to promote liver cancer metastasis. EMBO J 2022;:e110324. [PMID: 35451091 DOI: 10.15252/embj.2021110324] [Reference Citation Analysis]
290 Li J, Li MH, Wang TT, Liu XN, Zhu XT, Dai YZ, Zhai KC, Liu YD, Lin JL, Ge RL, Sun SH, Wang F, Yuan JH. SLC38A4 functions as a tumour suppressor in hepatocellular carcinoma through modulating Wnt/β-catenin/MYC/HMGCS2 axis. Br J Cancer 2021. [PMID: 34274945 DOI: 10.1038/s41416-021-01490-y] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
291 Guo J, Li W, Cheng L, Gao X. Identification and Validation of Hub Genes with Poor Prognosis in Hepatocellular Carcinoma by Integrated Bioinformatical Analysis. IJGM 2022;Volume 15:3933-41. [DOI: 10.2147/ijgm.s353708] [Reference Citation Analysis]
292 Ren S, Li Q, Liu S, Qi Q, Duan S, Mao B, Li X, Wu Y, Zhang L. Clinical Value of Machine Learning-Based Ultrasomics in Preoperative Differentiation Between Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma: A Multicenter Study. Front Oncol 2021;11:749137. [PMID: 34804935 DOI: 10.3389/fonc.2021.749137] [Reference Citation Analysis]
293 Dongiovanni P, Meroni M, Longo M, Fargion S, Fracanzani AL. Genetics, Immunity and Nutrition Boost the Switching from NASH to HCC. Biomedicines 2021;9:1524. [PMID: 34829753 DOI: 10.3390/biomedicines9111524] [Reference Citation Analysis]
294 Costentin C, Piñero F, Degroote H, Notarpaolo A, Boin IF, Boudjema K, Baccaro C, Podestá LG, Bachellier P, Ettorre GM, Poniachik J, Muscari F, Dibenedetto F, Hoyos Duque S, Salame E, Cillo U, Marciano S, Vanlemmens C, Fagiuoli S, Burra P, Van Vlierberghe H, Cherqui D, Lai Q, Silva M, Rubinstein F, Duvoux C, Boudjema K, Bachellier P, Conti F, Scatton O, Muscari F, Salame E, Bernard PH, Francoz C, Durand F, Dharancy S, Woehl M, Vanlemmens C, Laurent A, Radenne S, Dumortier J, Abergel A, Cherqui D, Barbier L, Houssel-debry P, Pageaux GP, Chiche L, Deledinghen V, Hardwigsen J, Gugenheim J, altieri M, Hilleret MN, Decaens T, Duvoux C, Piñero F, Chagas A, Costa P, Cristina de Ataide E, Quiñones E, Duque SH, Marciano S, Anders M, Varón A, Zerega A, Poniachik J, Soza A, Machaca MP, Arufe D, Menéndez J, Zapata R, Vilatoba M, Muñoz L, Menéndez RC, Maraschio M, Podestá LG, Mccormack L, Mattera J, Gadano A, Fatima Boin IS, Parente García JH, Carrilho F, Silva M, Notarpaolo A, Magini G, Miglioresi L, Gambato M, Benedetto FD, D’ambrosio C, Ettorre GM, Vitale A, Burra P, Fagiuoli S, Cillo U, Colledan M, Pinelli D, Magistri P, Vennarecci G, Colasanti M, Giannelli V, Pellicelli A, Baccaro C, Lai Q, Degroote H, Vlierberghe HV, Eduard C, Samuele I, Jeroen D, Jonas S, Jacques P, Chris V, Dirk Y, Peter M, Valerio L, Christophe M, Olivier D, Jean D, Roberto T, Paul LJ. R3-AFP score is a new composite tool to refine prediction of hepatocellular carcinoma recurrence after liver transplantation. JHEP Reports 2022. [DOI: 10.1016/j.jhepr.2022.100445] [Reference Citation Analysis]
295 Shi C, Li Y, Geng L, Shen W, Sui C, Dai B, Lu J, Pan M, Yang J. Adjuvant stereotactic body radiotherapy after marginal resection for hepatocellular carcinoma with microvascular invasion: A randomised controlled trial. Eur J Cancer 2022;166:176-84. [PMID: 35303509 DOI: 10.1016/j.ejca.2022.02.012] [Reference Citation Analysis]
296 Liu M, Huang Q, Zhu Y, Chen L, Li Y, Gong Z, Ai K. Harnessing reactive oxygen/nitrogen species and inflammation: Nanodrugs for liver injury. Materials Today Bio 2022. [DOI: 10.1016/j.mtbio.2022.100215] [Reference Citation Analysis]
297 Zhao LX, Zhang K, Shen BB, Li JN. Mesenchymal stem cell-derived exosomes for gastrointestinal cancer. World J Gastrointest Oncol 2021; 13(12): 1981-1996 [DOI: 10.4251/wjgo.v13.i12.1981] [Reference Citation Analysis]
298 Shen H, Liu B, Xu J, Zhang B, Wang Y, Shi L, Cai X. Circular RNAs: characteristics, biogenesis, mechanisms and functions in liver cancer. J Hematol Oncol 2021;14:134. [PMID: 34461958 DOI: 10.1186/s13045-021-01145-8] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
299 Kamimura K, Terai S. The promise of radiotherapy for hepatocellular carcinoma. Hepatol Res 2021;51:837-8. [PMID: 34346128 DOI: 10.1111/hepr.13687] [Reference Citation Analysis]
300 Cramer T, Vaupel P. Severe hypoxia is a typical characteristic of human hepatocellular carcinoma: Scientific fact or fallacy? J Hepatol 2022:S0168-8278(21)02305-9. [PMID: 34990751 DOI: 10.1016/j.jhep.2021.12.028] [Reference Citation Analysis]
301 Rizzo A, Ricci AD, Brandi G. Combining immune checkpoint inhibitors with locoregional therapies in hepatocellular carcinoma. Expert Review of Precision Medicine and Drug Development 2022;7:1-3. [DOI: 10.1080/23808993.2022.2020091] [Reference Citation Analysis]
302 Liao H, Jiang H, Chen Y, Duan T, Yang T, Han M, Xue Z, Shi F, Yuan K, Bashir MR, Shen D, Song B, Zeng Y. Predicting Genomic Alterations of Phosphatidylinositol-3 Kinase Signaling in Hepatocellular Carcinoma: A Radiogenomics Study Based on Next-Generation Sequencing and Contrast-Enhanced CT. Ann Surg Oncol 2022. [PMID: 35286532 DOI: 10.1245/s10434-022-11505-4] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
303 Sükei T, Palma E, Urbani L. Interplay between Cellular and Non-Cellular Components of the Tumour Microenvironment in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5586. [PMID: 34771746 DOI: 10.3390/cancers13215586] [Reference Citation Analysis]
304 Zhao X, Sun X, Huang W, Chen R, Chen K, Nie L, Fang C. A microenvironment-responsive FePt probes for imaging-guided Fenton-enhanced radiotherapy of hepatocellular carcinoma. J Nanobiotechnology 2022;20:100. [PMID: 35241082 DOI: 10.1186/s12951-022-01305-z] [Reference Citation Analysis]
305 Yu S, Wang H, Gao J, Liu L, Sun X, Wang Z, Wen P, Shi X, Shi J, Guo W, Zhang S. Identification of Context-Specific Fitness Genes Associated With Metabolic Rearrangements for Prognosis and Potential Treatment Targets for Liver Cancer. Front Genet 2022;13:863536. [DOI: 10.3389/fgene.2022.863536] [Reference Citation Analysis]
306 Lafnoune A, Lee S, Heo J, Daoudi K, Darkaoui B, Chakir S, Cadi R, Mounaji K, Shum D, Seo H, Oukkache N. Anti-Cancer Activity of Buthus occitanus Venom on Hepatocellular Carcinoma in 3D Cell Culture. Molecules 2022;27:2219. [DOI: 10.3390/molecules27072219] [Reference Citation Analysis]
307 Malagraba G, Yarmohammadi M, Javed A, Barceló C, Rubio-tomás T. The Role of LSD1 and LSD2 in Cancers of the Gastrointestinal System: An Update. Biomolecules 2022;12:462. [DOI: 10.3390/biom12030462] [Reference Citation Analysis]
308 Akbulut S, Tuncer A, Ogut Z, Sahin TT, Koc C. High-Level Procalcitonin in Patient with Mixed Fibrolamellar Hepatocellular Carcinoma: A Case Report and Literature Review. J Gastrointest Cancer 2021. [PMID: 34738189 DOI: 10.1007/s12029-021-00731-w] [Reference Citation Analysis]
309 Sun R, Zhang Z, Bao R, Guo X, Gu Y, Yang W, Wei J, Chen X, Tong L, Meng J, Zhong C, Zhang C, Zhang J, Sun Y, Ling C, Tong X, Yu F, Yu H, Qu W, Zhao B, Guo W, Qian M, Saiyin H, Liu Y, Liu R, Xie C, Liu W, Xiong Y, Guan K, Shi Y, Wang P, Ye D. Loss of SIRT5 promotes bile acid-induced immunosuppressive microenvironment and hepatocarcinogenesis. Journal of Hepatology 2022. [DOI: 10.1016/j.jhep.2022.02.030] [Reference Citation Analysis]
310 Turkbey B. Can BOLD fMRI Demonstrate Early Response to Chemoembolization in HCCs? Acad Radiol 2021:S1076-6332(21)00167-7. [PMID: 33958262 DOI: 10.1016/j.acra.2021.03.026] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
311 Kalasekar SM, VanSant-Webb CH, Evason KJ. Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities. Cancers (Basel) 2021;13:5524. [PMID: 34771685 DOI: 10.3390/cancers13215524] [Reference Citation Analysis]
312 Krishnamurthy S, Gilot D, Ahn SB, Lam V, Shin JS, Guillemin GJ, Heng B. Involvement of Kynurenine Pathway in Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5180. [PMID: 34680327 DOI: 10.3390/cancers13205180] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
313 Zhao M, Pan X, Yin Y, Hu H, Wei J, Bai Z, Tang W. Cost-Effectiveness Analysis of Five Systemic Treatments for Unresectable Hepatocellular Carcinoma in China: An Economic Evaluation Based on Network Meta-Analysis. Front Public Health 2022;10:869960. [DOI: 10.3389/fpubh.2022.869960] [Reference Citation Analysis]
314 Koskinas J, Armakolas A. Ariadne's Thread in the Network of Hepatocellular Carcinoma Immunobiology. J Clin Transl Hepatol 2021;9:279-80. [PMID: 34221912 DOI: 10.14218/JCTH.2021.00140] [Reference Citation Analysis]
315 Wang J, Wang C, Yang L, Li K. Identification of the critical genes and miRNAs in hepatocellular carcinoma by integrated bioinformatics analysis. Med Oncol 2022;39:21. [PMID: 34982264 DOI: 10.1007/s12032-021-01622-7] [Reference Citation Analysis]
316 Yang Y, Zhou Y, Zhang X, Xin Y, Chen Y, Fan Q, Li X, Wei X, Li Q, Zhou X, Zhou J. Using the aMAP Risk Score to Predict Late Recurrence Following Radiofrequency Ablation for Hepatocellular Carcinoma in Chinese Population: A Multicenter Study. J Hepatocell Carcinoma 2021;8:837-50. [PMID: 34350139 DOI: 10.2147/JHC.S308587] [Reference Citation Analysis]
317 Wu MZ, Yuan YC, Huang BY, Chen JX, Li BK, Fang JH, Zhuang SM. Identification of a TGF-β/SMAD/lnc-UTGF positive feedback loop and its role in hepatoma metastasis. Signal Transduct Target Ther 2021;6:395. [PMID: 34785655 DOI: 10.1038/s41392-021-00781-3] [Reference Citation Analysis]
318 Ahmad M, Dhasmana A, Harne PS, Zamir A, Hafeez BB. Chemokine Clouding and Liver Cancer Heterogeneity: Does it Impact Clinical Outcomes? Seminars in Cancer Biology 2022. [DOI: 10.1016/j.semcancer.2022.02.015] [Reference Citation Analysis]
319 Boilève A, Hilmi M, Delaye M, Tijeras-Raballand A, Neuzillet C. Biomarkers in Hepatobiliary Cancers: What is Useful in Clinical Practice? Cancers (Basel) 2021;13:2708. [PMID: 34070929 DOI: 10.3390/cancers13112708] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
320 Wang H, He X, Fang D, Wang X, Guan J, Shi Z, Chen X. Gemcitabine-facilitated modulation of the tumor microenvironment and PD-1/PD-L1 blockade generate a synergistic antitumor effect in a murine hepatocellular carcinoma model. Clinics and Research in Hepatology and Gastroenterology 2021. [DOI: 10.1016/j.clinre.2021.101853] [Reference Citation Analysis]
321 Romito I, Porru M, Braghini MR, Pompili L, Panera N, Crudele A, Gnani D, De Stefanis C, Scarsella M, Pomella S, Levi Mortera S, de Billy E, Conti AL, Marzano V, Putignani L, Vinciguerra M, Balsano C, Pastore A, Rota R, Tartaglia M, Leonetti C, Alisi A. Focal adhesion kinase inhibitor TAE226 combined with Sorafenib slows down hepatocellular carcinoma by multiple epigenetic effects. J Exp Clin Cancer Res 2021;40:364. [PMID: 34784956 DOI: 10.1186/s13046-021-02154-8] [Reference Citation Analysis]
322 Zou Y, Chen Z, Lou Q, Han H, Zhang Y, Chen Z, Ma Z, Shi N, Jin H. A Novel Blood Index-Based Model to Predict Hepatitis B Virus-Associated Hepatocellular Carcinoma Recurrence After Curative Hepatectomy: Guidance on Adjuvant Transcatheter Arterial Chemoembolization Choice. Front Oncol 2021;11:755235. [PMID: 35004275 DOI: 10.3389/fonc.2021.755235] [Reference Citation Analysis]
323 Li Y, Zou L, Liu X, Luo J, Liu H. Identification of Immune-Related Genes for Establishment of Prognostic Index in Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:760079. [PMID: 34796177 DOI: 10.3389/fcell.2021.760079] [Reference Citation Analysis]
324 Filippi L, Schillaci O. Total-body [18F]FDG PET/CT scan has stepped into the arena: the faster, the better. Is it always true? Eur J Nucl Med Mol Imaging 2022. [PMID: 35396968 DOI: 10.1007/s00259-022-05791-z] [Reference Citation Analysis]
325 Karunakaran CP, Burgess MT, Rao MB, Holland CK, Mast TD. Effect of Overpressure on Acoustic Emissions and Treated Tissue Histology in ex Vivo Bulk Ultrasound Ablation. Ultrasound Med Biol 2021;47:2360-76. [PMID: 34023187 DOI: 10.1016/j.ultrasmedbio.2021.04.006] [Reference Citation Analysis]
326 Chen J, Tao Q, Lang Z, Gao Y, Jin Y, Li X, Wang Y, Zhang Y, Yu S, Lv B, Yu Z, Lin C, Duan B. Signature Construction and Molecular Subtype Identification Based on Pyroptosis-Related Genes for Better Prediction of Prognosis in Hepatocellular Carcinoma. Oxidative Medicine and Cellular Longevity 2022;2022:1-20. [DOI: 10.1155/2022/4494713] [Reference Citation Analysis]
327 Shi H, Zhong F, Yi X, Shi Z, Ou F, Zuo Y, Xu Z. The Construction of a Prognostic Model Based on a Peptidyl Prolyl Cis-Trans Isomerase Gene Signature in Hepatocellular Carcinoma. Front Genet 2021;12:730141. [PMID: 34887898 DOI: 10.3389/fgene.2021.730141] [Reference Citation Analysis]
328 Salman S, Meyers DJ, Wicks EE, Lee SN, Datan E, Thomas AM, Anders NM, Hwang Y, Lyu Y, Yang Y, Jackson W, Dordai D, Rudek MA, Semenza GL. HIF inhibitor 32-134D eradicates murine hepatocellular carcinoma in combination with anti-PD1 therapy. Journal of Clinical Investigation 2022;132:e156774. [DOI: 10.1172/jci156774] [Reference Citation Analysis]
329 Mohammadi A, Pour Abbasi MS, Khorrami S, Khodamoradi S, Mohammadi Goldar Z, Ebrahimzadeh F. The TRIM proteins in cancer: from expression to emerging regulatory mechanisms. Clin Transl Oncol 2021. [PMID: 34643877 DOI: 10.1007/s12094-021-02715-5] [Reference Citation Analysis]
330 Tan AT, Meng F, Jin J, Zhang JY, Wang SY, Shi L, Shi M, Li Y, Xie Y, Liu LM, Zhou CB, Chua A, Ho ZZ, Luan J, Zhao J, Li J, Wai LE, Koh S, Wang T, Bertoletti A, Wang FS. Immunological alterations after immunotherapy with short lived HBV-TCR T cells associates with long-term treatment response in HBV-HCC. Hepatol Commun 2021. [PMID: 34935312 DOI: 10.1002/hep4.1857] [Reference Citation Analysis]
331 El-Mahdy HA, Sallam AM, Ismail A, Elkhawaga SY, Elrebehy MA, Doghish AS. miRNAs inspirations in hepatocellular carcinoma: Detrimental and favorable aspects of key performers. Pathol Res Pract 2022;233:153886. [PMID: 35405621 DOI: 10.1016/j.prp.2022.153886] [Reference Citation Analysis]
332 Wang Y, Zhao Q, Zhao B, Zheng Y, Zhuang Q, Liao N, Wang P, Cai Z, Zhang D, Zeng Y, Liu X. Remodeling Tumor-Associated Neutrophils to Enhance Dendritic Cell-Based HCC Neoantigen Nano-Vaccine Efficiency. Adv Sci (Weinh) 2022;:e2105631. [PMID: 35142445 DOI: 10.1002/advs.202105631] [Reference Citation Analysis]
333 Samaržija I. Wnt Signaling Pathway Is among the Drivers of Liver Metastasis. Livers 2021;1:180-200. [DOI: 10.3390/livers1040015] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
334 Newsome RC, Yang Y, Jobin C. The microbiome, gastrointestinal cancer, and immunotherapy. J Gastroenterol Hepatol 2021. [PMID: 34820895 DOI: 10.1111/jgh.15742] [Reference Citation Analysis]
335 Coto-Llerena M, Benjak A, Gallon J, Meier MA, Boldanova T, Terracciano LM, Ng CKY, Piscuoglio S. Circulating Cell-Free DNA Captures the Intratumor Heterogeneity in Multinodular Hepatocellular Carcinoma. JCO Precis Oncol 2022;6:e2100335. [PMID: 35263170 DOI: 10.1200/PO.21.00335] [Reference Citation Analysis]
336 Lee I, Chao Y, Lee P, Chen S, Chi C, Wu C, Wu K, Hou M, Huang Y. Determinants of Survival and Post-Progression Outcomes by Sorafenib–Regorafenib Sequencing for Unresectable Hepatocellular Carcinoma. Cancers 2022;14:2014. [DOI: 10.3390/cancers14082014] [Reference Citation Analysis]
337 Tu H, Wang W, Feng Y, Zhang L, Zhou H, Cheng C, Ji L, Cai Q, Feng Y. β-Patchoulene represses hypoxia-induced proliferation and epithelial-mesenchymal transition of liver cancer cells. Bioengineered 2022;13:11907-22. [PMID: 35546067 DOI: 10.1080/21655979.2022.2065945] [Reference Citation Analysis]
338 Zhan S, Yang P, Zhou S, Xu Y, Xu R, Liang G, Zhang C, Chen X, Yang L, Jin F, Wang Y. Serum mitochondrial tsRNA serves as a novel biomarker for hepatocarcinoma diagnosis. Front Med 2022. [PMID: 35416630 DOI: 10.1007/s11684-022-0920-7] [Reference Citation Analysis]
339 Wang Y, Liu D, Zhang T, Xia L. FGF/FGFR Signaling in Hepatocellular Carcinoma: From Carcinogenesis to Recent Therapeutic Intervention. Cancers (Basel) 2021;13:1360. [PMID: 33802841 DOI: 10.3390/cancers13061360] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
340 Wu L, Yang FR, Xing ML, Lu SF, Chen HL, Yang QW, Zhang YT, Lu Y, Huang Y. Multi-material basis and multi-mechanisms of the Dahuang Zhechong pill for regulating Treg/Th1 balance in hepatocellular carcinoma. Phytomedicine 2022;100:154055. [PMID: 35344716 DOI: 10.1016/j.phymed.2022.154055] [Reference Citation Analysis]
341 Lu I, Lin S, Chu Y, Wen Y, Lin Y, Cheng W, Sheu J, Lin C. (−)-Agelasidine A Induces Endoplasmic Reticulum Stress-Dependent Apoptosis in Human Hepatocellular Carcinoma. Marine Drugs 2022;20:109. [DOI: 10.3390/md20020109] [Reference Citation Analysis]
342 Ju S, Zhou C, Hu J, Wang Y, Wang C, Liu J, Yang C, Huang S, Li T, Chen Y, Bai Y, Yao W, Xiong B. Late combination of transarterial chemoembolization with apatinib and camrelizumab for unresectable hepatocellular carcinoma is superior to early combination. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09451-1] [Reference Citation Analysis]
343 Pinyol R, Torrecilla S, Wang H, Montironi C, Piqué-Gili M, Torres-Martin M, Wei-Qiang L, Willoughby CE, Ramadori P, Andreu-Oller C, Taik P, Lee YA, Moeini A, Peix J, Faure-Dupuy S, Riedl T, Schuehle S, Oliveira CP, Alves VA, Boffetta P, Lachenmayer A, Roessler S, Minguez B, Schirmacher P, Dufour JF, Thung SN, Reeves HL, Carrilho FJ, Chang C, Uzilov AV, Heikenwalder M, Sanyal A, Friedman SL, Sia D, Llovet JM. Molecular characterisation of hepatocellular carcinoma in patients with non-alcoholic steatohepatitis. J Hepatol 2021:S0168-8278(21)00326-3. [PMID: 33992698 DOI: 10.1016/j.jhep.2021.04.049] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
344 Yao J, Zhu X, Wu Z, Wei Q, Cai Y, Zheng Y, Hu X, Hu H, Zhang X, Pan H, Zhong X, Han W. Efficacy and safety of PD-1 inhibitor combined with antiangiogenic therapy for unresectable hepatocellular carcinoma: A multicenter retrospective study. Cancer Med 2022. [PMID: 35403359 DOI: 10.1002/cam4.4747] [Reference Citation Analysis]
345 Elms D, Badami A, Dhanarajan A. Systemic Therapy in Metastatic Hepatocellular Carcinoma. Curr Gastroenterol Rep 2022. [PMID: 35416635 DOI: 10.1007/s11894-022-00842-9] [Reference Citation Analysis]
346 Zhao S, Zhang L, Deng L, Ouyang J, Xu Q, Gao X, Zeng Z, Liu YN. NIR-II Responsive Hydrogel as an Angiogenesis Inhibition Agent for Tumor Microenvironment Reprogramming. Small 2021;17:e2103003. [PMID: 34561966 DOI: 10.1002/smll.202103003] [Reference Citation Analysis]
347 Kurma K, Manches O, Chuffart F, Sturm N, Gharzeddine K, Zhang J, Mercey-Ressejac M, Rousseaux S, Millet A, Lerat H, Marche PN, Macek Jilkova Z, Decaens T. DEN-Induced Rat Model Reproduces Key Features of Human Hepatocellular Carcinoma. Cancers (Basel) 2021;13:4981. [PMID: 34638465 DOI: 10.3390/cancers13194981] [Reference Citation Analysis]
348 Chen S, Zhu JY, Zang X, Zhai YZ. The Emerging Role of Ferroptosis in Liver Diseases. Front Cell Dev Biol 2021;9:801365. [PMID: 34970553 DOI: 10.3389/fcell.2021.801365] [Reference Citation Analysis]
349 Claasen MPAW, Ivanics T, Gravely A, Sapisochin G. Prognostic risk scores for liver transplantation: game changers or statistical artworks? Hepatobiliary Surg Nutr 2021;10:553-7. [PMID: 34430542 DOI: 10.21037/hbsn-21-258] [Reference Citation Analysis]
350 Yao LQ, Chen ZL, Feng ZH, Diao YK, Li C, Sun HY, Zhong JH, Chen TH, Gu WM, Zhou YH, Zhang WG, Wang H, Zeng YY, Wu H, Wang MD, Xu XF, Pawlik TM, Lau WY, Shen F, Yang T. Clinical Features of Recurrence After Hepatic Resection for Early-Stage Hepatocellular Carcinoma and Long-Term Survival Outcomes of Patients with Recurrence: A Multi-institutional Analysis. Ann Surg Oncol 2022. [PMID: 35192156 DOI: 10.1245/s10434-022-11454-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
351 Pfister D, Núñez NG, Pinyol R, Govaere O, Pinter M, Szydlowska M, Gupta R, Qiu M, Deczkowska A, Weiner A, Müller F, Sinha A, Friebel E, Engleitner T, Lenggenhager D, Moncsek A, Heide D, Stirm K, Kosla J, Kotsiliti E, Leone V, Dudek M, Yousuf S, Inverso D, Singh I, Teijeiro A, Castet F, Montironi C, Haber PK, Tiniakos D, Bedossa P, Cockell S, Younes R, Vacca M, Marra F, Schattenberg JM, Allison M, Bugianesi E, Ratziu V, Pressiani T, D'Alessio A, Personeni N, Rimassa L, Daly AK, Scheiner B, Pomej K, Kirstein MM, Vogel A, Peck-Radosavljevic M, Hucke F, Finkelmeier F, Waidmann O, Trojan J, Schulze K, Wege H, Koch S, Weinmann A, Bueter M, Rössler F, Siebenhüner A, De Dosso S, Mallm JP, Umansky V, Jugold M, Luedde T, Schietinger A, Schirmacher P, Emu B, Augustin HG, Billeter A, Müller-Stich B, Kikuchi H, Duda DG, Kütting F, Waldschmidt DT, Ebert MP, Rahbari N, Mei HE, Schulz AR, Ringelhan M, Malek N, Spahn S, Bitzer M, Ruiz de Galarreta M, Lujambio A, Dufour JF, Marron TU, Kaseb A, Kudo M, Huang YH, Djouder N, Wolter K, Zender L, Marche PN, Decaens T, Pinato DJ, Rad R, Mertens JC, Weber A, Unger K, Meissner F, Roth S, Jilkova ZM, Claassen M, Anstee QM, Amit I, Knolle P, Becher B, Llovet JM, Heikenwalder M. NASH limits anti-tumour surveillance in immunotherapy-treated HCC. Nature 2021;592:450-6. [PMID: 33762733 DOI: 10.1038/s41586-021-03362-0] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
352 Su H, Tang Y, Nie K, Wang Z, Wang H, Dong H, Chen G. Identification Prognostic Value and Correlation with Tumor-Infiltrating Immune Cells of Tripartite-Motif Family Genes in Hepatocellular Carcinoma. IJGM 2022;Volume 15:1349-63. [DOI: 10.2147/ijgm.s341018] [Reference Citation Analysis]
353 Da B, Luo S, Huang M, Song F, Ding R, Xiao Y, Fu Y, Yang Y, Wang H, Khalaf OI. Prediction of Hepatocellular Carcinoma Prognosis and Immune Cell Infiltration Using Gene Signature Associated with Inflammatory Response. Computational and Mathematical Methods in Medicine 2022;2022:1-24. [DOI: 10.1155/2022/2415129] [Reference Citation Analysis]
354 Jain D, Chaudhary P, Varshney N, Bin Razzak KS, Verma D, Khan Zahra TR, Janmeda P, Sharifi-Rad J, Daştan SD, Mahmud S, Docea AO, Calina D. Tobacco Smoking and Liver Cancer Risk: Potential Avenues for Carcinogenesis. J Oncol 2021;2021:5905357. [PMID: 34925509 DOI: 10.1155/2021/5905357] [Reference Citation Analysis]
355 Mattos ÂZ, Debes JD, Boonstra A, Vogel A, Mattos AA. Immune aspects of hepatocellular carcinoma: From immune markers for early detection to immunotherapy. World J Gastrointest Oncol 2021; 13(9): 1132-1143 [PMID: 34616518 DOI: 10.4251/wjgo.v13.i9.1132] [Reference Citation Analysis]
356 Zhou Y, Hu J, Liu L, Yan M, Zhang Q, Song X, Lin Y, Zhu D, Wei Y, Fu Z, Hu L, Chen Y, Li X. Gly-tRF enhances LCSC-like properties and promotes HCC cells migration by targeting NDFIP2. Cancer Cell Int 2021;21:502. [PMID: 34537070 DOI: 10.1186/s12935-021-02102-8] [Reference Citation Analysis]
357 Zhang D, Zhang K, Protzer U, Zeng C. HBV Integration Induces Complex Interactions between Host and Viral Genomic Functions at the Insertion Site. J Clin Transl Hepatol 2021;9:399-408. [PMID: 34221926 DOI: 10.14218/JCTH.2021.00062] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
358 Radjenović B, Sabo M, Šoltes L, Prnova M, Čičak P, Radmilović-Radjenović M. On Efficacy of Microwave Ablation in the Thermal Treatment of an Early-Stage Hepatocellular Carcinoma. Cancers (Basel) 2021;13:5784. [PMID: 34830937 DOI: 10.3390/cancers13225784] [Reference Citation Analysis]
359 Guo J, Wang W, Zhang Y, Xu L, Kong J. Comparison of initial tumor responses to transarterial bland embolization and drug-eluting beads-transarterial chemoembolization in the management of hepatocellular carcinoma: a propensity-score matching analysis. J Gastrointest Oncol 2021;12:1838-50. [PMID: 34532132 DOI: 10.21037/jgo-21-370] [Reference Citation Analysis]
360 Li S, Xie Y, Wang G, Zhang L, Zhou W. Attention guided discriminative feature learning and adaptive fusion for grading hepatocellular carcinoma with Contrast-enhanced MR. Computerized Medical Imaging and Graphics 2022. [DOI: 10.1016/j.compmedimag.2022.102050] [Reference Citation Analysis]
361 Wang Y, Zhang T, Sun M, Ji X, Xie M, Huang W, Xia L. Therapeutic Values of Myeloid-Derived Suppressor Cells in Hepatocellular Carcinoma: Facts and Hopes. Cancers (Basel) 2021;13:5127. [PMID: 34680276 DOI: 10.3390/cancers13205127] [Reference Citation Analysis]
362 Zheng Ms B, Wang Ms H, Wang Ms JX, Liu Ms ZH, Zhang Md P, Zhang Md D. The Clinical Significance of RMI2 in Hepatocellular Carcinoma. Technol Cancer Res Treat 2021;20:15330338211045496. [PMID: 34634948 DOI: 10.1177/15330338211045496] [Reference Citation Analysis]
363 Ozer M, George A, Goksu SY, George TJ, Sahin I. The Role of Immune Checkpoint Blockade in the Hepatocellular Carcinoma: A Review of Clinical Trials. Front Oncol 2021;11:801379. [PMID: 34956912 DOI: 10.3389/fonc.2021.801379] [Reference Citation Analysis]
364 Zeng Q, Klein C, Caruso S, Maille P, Laleh NG, Sommacale D, Laurent A, Amaddeo G, Gentien D, Rapinat A, Regnault H, Charpy C, Nguyen CT, Tournigand C, Brustia R, Pawlotsky JM, Kather JN, Maiuri MC, Loménie N, Calderaro J. Artificial intelligence predicts immune and inflammatory gene signatures directly from hepatocellular carcinoma histology. J Hepatol 2022:S0168-8278(22)00031-9. [PMID: 35143898 DOI: 10.1016/j.jhep.2022.01.018] [Reference Citation Analysis]
365 Li R, Liu R, Zheng S, Liu W, Li H, Li D, Granito A. Comprehensive Analysis of Prognostic Value and Immune Infiltration of the NT5DC Family in Hepatocellular Carcinoma. Journal of Oncology 2022;2022:1-13. [DOI: 10.1155/2022/2607878] [Reference Citation Analysis]
366 Esagian SM, Kakos CD, Giorgakis E, Burdine L, Barreto JC, Mavros MN. Adjuvant Transarterial Chemoembolization Following Curative-Intent Hepatectomy Versus Hepatectomy Alone for Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Cancers (Basel) 2021;13:2984. [PMID: 34203692 DOI: 10.3390/cancers13122984] [Reference Citation Analysis]
367 Cassese G, Han H, Lee B, Lee HW, Cho JY, Troisi R. Leaping the Boundaries in Laparoscopic Liver Surgery for Hepatocellular Carcinoma. Cancers 2022;14:2012. [DOI: 10.3390/cancers14082012] [Reference Citation Analysis]
368 Caviglia GP, Troshina G, Santaniello U, Rosati G, Bombaci F, Birolo G, Nicolosi A, Saracco GM, Ciancio A. Long-Term Hepatocellular Carcinoma Development and Predictive Ability of Non-Invasive Scoring Systems in Patients with HCV-Related Cirrhosis Treated with Direct-Acting Antivirals. Cancers 2022;14:828. [DOI: 10.3390/cancers14030828] [Reference Citation Analysis]
369 Zane KE, Makary MS. Locoregional Therapies for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis. Cancers (Basel) 2021;13:5430. [PMID: 34771593 DOI: 10.3390/cancers13215430] [Reference Citation Analysis]
370 Rizzo A. Locoregional treatments plus immunotherapy in hepatocellular carcinoma: where do we stand? Future Oncol 2022. [PMID: 35193371 DOI: 10.2217/fon-2021-1623] [Reference Citation Analysis]
371 Wu S, Liu S, Li Y, Liu C, Pan H. Lestaurtinib Has the Potential to Inhibit the Proliferation of Hepatocellular Carcinoma Uncovered by Bioinformatics Analysis and Pharmacological Experiments. Front Cell Dev Biol 2022;10:837428. [DOI: 10.3389/fcell.2022.837428] [Reference Citation Analysis]
372 Al-Malki AL, Bakkar A, Huwait EA, Barbour EK, Abulnaja KO, Kumosani TA, Moselhy SS. Strigol1/albumin/chitosan nanoparticles decrease cell viability, induce apoptosis and alter metabolomics profile in HepG2 cancer cell line. Biomed Pharmacother 2021;142:111960. [PMID: 34352718 DOI: 10.1016/j.biopha.2021.111960] [Reference Citation Analysis]
373 Lan HY, An P, Liu QP, Chen YY, Yu YY, Luan X, Tang JY, Zhang H. Aidi injection induces apoptosis of hepatocellular carcinoma cells through the mitochondrial pathway. J Ethnopharmacol 2021;274:114073. [PMID: 33794335 DOI: 10.1016/j.jep.2021.114073] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
374 Wang Z, Chen N, Li Z, Xu G, Zhan X, Tang J, Xiao X, Bai Z. The Cytosolic DNA-Sensing cGAS-STING Pathway in Liver Diseases. Front Cell Dev Biol 2021;9:717610. [PMID: 34386500 DOI: 10.3389/fcell.2021.717610] [Reference Citation Analysis]